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1.  Introduction 
1.1.  Research basis 
1.1.1. Tissue engineering and human mesenchymal stem cells 
(hMSCs) 
Tissue and organ defect or dysfunctions were hard to treat. Large scale bone loss 
after tumor resection or trauma needed to be refilled by autogenous bone or allograft 
bone. As immune rejection and possible propagation of infectious disease limited 
usage of allogeneic graft, restricted bone-harvesting amount and donor sites limited 
the usage of autogenuous bone graft, a new strategy to reconstruct bone and other 
tissue defect (cartilage, tendon, etc) or even to rehabilitate organ function needed to 
be exploited. 
 
“Tissue engineering” was the application of the principles and methods of 
engineering and the life sciences towards the development of biological substitutes to 
restore, maintain or improve functions. In the USA it had been actively fostered by the 
“National Science Foundation”, both through research grants and the sponsorship of a 
series of workshops starting in 1988 (Nerem 1992). Cell transplantation and tissue 
engineering techniques were being developed to generate new functional tissues for 
human applications. New techniques had been developed to generate new bone, 
cartilage and even liver tissue for reconstruction or replacement therapy.  
 
Devices were constructed using synthetic polymers as scaffold attached to 
tissue-specific cells were seeded on crude (coral, silk, alginate, etc) or synthetic 
(polylactic acid, PLA, polyglycolic acid, PGA, etc) scaffolds, different types of tissues 
were engineered in static or dynamic culture devices, thereby allowing for tissue 
remodeling and functional replacement. Basically there were three aspects of tissue 
engineering: seed cell, scaffold and in vitro culture system (device) to construct 
tissue-engineered tissue or organ.  
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Many different cell types had been employed to construct tissue and organ. 
Autologous somatic cells seemed to be a good choice for its autologous feature 
without causing any immune rejection, but resource of autologous somatic cells were 
limited, collecting of autologous somatic cells would cause damage to original 
unimpaired tissue and these cells were mostly inert to proliferation, these would limit 
the application of autologous somatic cell for tissue engineering. Allogeneic cells were 
relatively easier to attain, but due to the problem of possible immune rejection and 
disease contamination, their usage in tissue engineering was also limited.   
 
Human mesenchymal stem cells (hMSCs) represented a non-hematopoietic cell 
population in bone marrow with the ability of self-renewing and multi-lineage 
differentiation. hMSCs could be easily separated from bone marrow or adipose tissue  
by penetration and aspiration. Isolation and characterization of hMSCs had been 
performed by investigators using a variety of techniques including gradient 
centrifugation, plastic adherence, antibodies-mediated fluorescence-activated cell 
sorting (FACS), fibronectin-mediated adherence in low serum condition or in vitro 
growth selection under low oxygen tension in the presence of hematopoietic cells. 
Many researches proved in vitro and in vivo that hMSCss not only possessed 
prominent capacity to duplicate themselves (self-renewal) to serve as a cell source 
reservoir for cell replacement and tissue regeneration, but also had multi-lineage 
differentiation potential, which could be induced to differentiate into different 
mesoderm type cells including osteoblasts, chondrocytes, adipocytes, myocytes, and 
even into other non-mesodermal lineages, such as hepatic and Schwann cell-like 
myelinating cells (Pittenger et al. 1999). Based on their high reproductivity of 
generating progeny cells, multi-lineage differentiation potential and relative easiness 
to separate, autogenous hMSCs could be adapted as a promising seed cell candidate 
for tissue engineering without causing any immune responses.  
1.1.2. Senescence and telomerase 
Although hMSCs was recognized to have noticeable self-renewing capacity, the 
abundance of hMSCs in bone marrow was very low (about 1/105-1/104), when large 
amount of hMSCs was needed for construction of a large scale tissue or a specific 
organ in vitro, small amount of initial separated cells needed to be passaged and 
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expanded in vitro for relatively long period and more than 10 passages until enough 
cell number for tissue engineering. During the long period of passage in vitro, due to 
high concentration of oxygen (20% in incubator, while 3%-5% in vivo), toxic 
substances, malnourishment in culture system, the growth rate of hMSCs would be 
slowed down; cells would become flat, show increased adherence to the culture 
vessel, change their molecular expression profile and even lose their differentiation 
potential. This was a common phenomenon faced by cells in culture and most of 
somatic cells in living organism — replicative senescence.   
 
Senescence was originally defined as an ‘irreversible’ state of cell cycle arrest that 
reflected consumed proliferative capacity of the cell (Hayflick limit). In eukaryotic cells, 
each chromosome shortened from telomeres during every round of DNA replication 
due to end-replication problem of DNA polymerase. The structure of telomeres with 
repetitive sequences (TTAGGG) n functioned as a cap to prevent chromosome end 
fusions and genomic instability (Collins and Mitchell 2002;de Lange 2006). While 
germ cells expressed telomerase, which resynthesized the telomeric repeats to 
maintain the chromosomal length, most human somatic cells did not express 
telomerase, consequently these telomerase-shortage somatic cells got into 
senescence after limited time of in vitro culture. Although hMSCs was recognized to 
have noticeable self-renewing capacity, no telomerase activity was detectable in 
these cells by nowadays well accepted telomeric repeat amplification protocol (TRAP) 
method. Telomere length in hMSCs was also not significantly longer than normal 
somatic cells.  
 
In cells proliferating continuously, attrition of telomeres beyond a threshold triggered a 
response leading to replicative senescence. Recent studies had indicated that 
telomere attrition provoke DNA damage-responsive signaling pathways, such as 
tumor suppressing “cyclin-dependent kinase inhibitor 2A (p16INK4a) - retinoblastoma 1 
(RB1)” and “alternative reading frame (p14ARF) - tumor protein 53 (TP53)” pathways, 
to induce cell cycle control and replicative senescence (Kiyokawa 2006). 
 
Telomerase had the enzymatic activity to maintain and elongate telomere length. It 
contained three components. The essential catalytic component was telomerase 
reverse transcriptase (TERT), which provided the catalytic center for addition of 
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telomere-specific sequence (TTAGGG) n to the end of telomeres. The other two 
important components were the synthesis template of telomere - telomerase RNA 
component (TERC) and additional function-modulating proteins (Figure 1). Since 
TERT was the key catalytic unit of telomerase, ectopic expression of TERT was 
proved to be able to maintain the telomere length in cells, thus prevent cells from 
replicative senescence and loss of function (Cech 2004).  
 
 
 
Figure 1. Schematic illustration of telomerase in Action. The RNA subunit (purple)-TERC had the 
template sequence of Tetrahymena telomerase. Proteins included the catalytic subunit, TERT (yellow), 
and additional less-conserved proteins (orange). [6] 
1.1.3. Immortalization of hMSCs by human telomerase reverse 
transcriptase (hTERT) transduction 
Since there was no detectable telomerase activity in hMSCs, then transduction of 
hMSCs with hTERT could be a practical way to bypass senescence and extend the 
lifespan of hMSCs. Many authors had gained successful results using non-viral or 
viral vectors to transfect cells with hTERT and immortalized human endothelial cell, 
hematopoietic progenitor cell, bone marrow stromal cell, fibroblast-like cell from 
embryonic stem cell, adipose tissue-derived stromal cell, osteoblast from hMSCs, 
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umbilical cord blood-derived cells, et al (Zimmermann et al. 2004;Xu et al. 
2004;Ramirez et al. 2004;Jun et al. 2004) (Table 1).  
 
 
Table 1. hTERT immortalization of somatic cells (Harley 2002) 
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Most of these authors used traditional Moloney murine leukemia virus (MoMLV) – 
based retroviral systems to transduce cells, but MoMLV–based retroviral vectors 
could only infect dividing cells, therefore limited their application in non-dividing cells. 
And due to their integration bias for transcription start site (TSS) and 
cancer-associated genes, cells tranduced with MoMLV–based retroviral vectors were 
predisposed to malignant transformation. Meanwhile, human immunodeficiency virus 
(HIV)-1-based lentiviral vectors could infect both dividing and non-dividing cells, and  
had superior proficiency at integrating into cells without TSS or cancer-associated 
genes preference, therefore lentiviral vectors could be a better choice for transferring 
gene of interest (GOI) into target cells.   
In our experiment, lentiviral vector would be employed to transfer hTERT gene into 
hMSCs, and the resulting expression of hTERT and senescence-bypassing function 
of hTERT transduction would also be explored. 
1.1.4. Importance of examination of malignant transformation 
potential of hTERT-transduced hMSCs 
 
hTERT transduction could bypass senescence and expand life span of hMSCs, but 
according to some authors’ observations, hTERT transduction was reported to have 
tumorigenic potential that it could predispose hMSCs to chromosome instability, or 
even neoplastic transformation. Serakinci et al noticed that, long-term in vitro culture 
of retrovirally hTERT-immortalized hMSCs had high incidence of neoplastic 
transformation and alteration in tumor related genes, such as v-Ki-ras2 Kirsten rat 
sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral oncogene 
homolog (NRAS), cyclin-dependent kinase inhibitor 2A/alternative reading frame 
(Ink4a/ARF), deleted in bladder cancer chromosome region candidate 1 (DBCCR1) 
(Serakinci et al. 2004). Noble et al noticed altered TP53, cyclin-dependent kinase 
inhibitor 1A (p21) expression and deletion of chromosome in hTERT-immortalized 
human fibroblasts after long term in vitro culture (Noble et al. 2004).   
 
One thing to be noticed in these observations was that, all of the chromosome 
abnormalities were detected in TERT-transduced cells after long term continuous in 
vitro culture. Miura et al had observed that, murine bone marrow-derived MSCs, 
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without any aberrance in chromosome at the beginning of the observation, had 
acquired spontaneous accumulated chromosomal abnormalities and malignant 
transformation after numerous in vitro passages. They also noticed that this 
transformation was associated with increased oncogene v-myc myelocytomatosis 
viral oncogene homolog (c-myc) expression (Miura et al. 2006).  Based on these 
observation and the  proved tumorigenic potential of commonly used MoMLV–based 
retroviral vectors, one speculation could be prompted that, it could be the 
accumulated chromosomal instability during long-term in vitro culture and the specific 
trait of retroviral vectors used in hTERT transduction that predispose 
hTERT-transduced hMSCs to neoplastic transformation in the observations above.  
 
In order to check and exclude the potential malignant transformation of our lentivirally 
hTERT-transduced cells, karyotyping of chromosomes, soft agar assay of 
anchorage-independence and nude mice implantation assay would be employed. As 
the normal prosperous self-renewal proliferation of stem cells was under surveillance 
by two important tumor suppressing pathways—RB1 and TP53. The expression of 
these tumor suppressing genes would be monitored along with the time course of 
continuous in vitro culture of our lentivirally hTERT-transduced hMSCs.    
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1.2.  Aim of the experiment. 
1.2.1. To establish immortalized hMSCs cell line by lentiviral hTERT - transduction 
and single cell picking. 
1.2.2. To explore the effect of hTERT on the biological behaviour of hMSCs. 
1.2.3 To explore the potential transformation capacity of lentiviral hTERT-transduction 
in hMSCs. 
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2.  Material and Methods 
2.1.  Culture of human mesenchymal stem cells (hMSCs)  
Material:  
Cells: As proposed by the “Mesenchymal and tissue stem cell committee of the 
international society for cellular therapy”, three criteria should be fulfilled to define 
MSCs. First, MSC needed to be plastic-adherent when maintained in standard culture 
conditions using tissue culture flasks. Second, more than 95% of the MSC population 
needed to express specific mesenchymal stem cell markers such as cluster of 
differentiation (CD) 105 as measured by flow cytometry; and lack expression of 
hematopoietic cell markers such as CD14, CD34 and CD45 (elucidated in table 2). 
Third, the cells needed to be able to differentiate to osteoblasts, adipocytes and 
chondroblasts under standard in vitro differentiation conditions (Dominici et al. 
2006;Horwitz et al. 2005). 
 
Human mesenchymal stem cells (Catalog Number-Cat. No: POPT-2501, 
cryopreserved) were purchased from Cambrex (Lonza) Corporation USA. Human 
bone marrow was withdrawn from the posterior iliac crest of the pelvic bone of normal 
volunteers, centrifuged with density gradient method, plated into culture flask followed 
by sequential medium change to eliminate non-adherent hematopoietic cells. The 
cells were passaged and obtained at the 3rd passage after isolation. All cells were 
tested negative for HIV-1, hepatitis-B and C, mycoplasma, bacteria, yeast and fungi. 
Cells were tested for purity by flow cytometry and analyzed for surface markers, which 
were positive for CD105, CD166, CD29 and CD44 and negative for CD14, CD34 and 
CD45 (Table 2). All Cells were also performance assayed and certified to have the 
ability to differentiate into osteogenic, chondrogenic and adipogenic lineages (Figure 
2).  
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  Alternative name Cellular function 
Positive 
CD105 Endoglin 
a. Component of the transforming growth factor 
(TGF) β receptor complex. 
b. Modulator of cellular responses to TGF-β 1. 
CD166 
Stem cell antigen-1 
(SC-1) 
Cell adhesion. 
CD29 
Integrin, β1 (fibronectin 
receptor) 
Cell adhesion and recognition. 
CD44 
Homing-associated cell 
adhesion molecule 
(H-CAM) 
a. Recyclable receptor for hyaluronic acid (HA). 
b. Interacting also with other ligands such as 
osteopontin, collagens, and matrix 
metalloproteinases-MMPs. 
Negative 
CD14 
Lipopolysaccharide 
(LPS) receptor 
a. Surface protein preferentially expressed on 
monocytes / macrophages. 
b. Binding with lipopolysaccharide binding protein 
and apoptotic cells. 
CD34 Glycoprotein 105-120 
a. Cell-cell adhesion. 
b. Inhibition of hematopoietic differentiation. 
c. Cell surface antigen selectively expressed on 
human hematopoietic progenitor cells. 
CD45 
a. Leukocyte common 
antigen (LCA) 
b. Protein tyrosine 
phosphatase, receptor 
type C 
T and B cell antigen receptor-mediated activation. 
 
 
Table 2. Surface makers tested for purity of hMSCs by Cambrex 
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Figure.2 Differentiation assay of hMSCs from Cambrex. hMSCs were stained positive for fat droplets 
(a), collagen II (b), alkaline phosphatase（ALP）and extracellular  calcium deposition (c) after adipo-, 
chondro-, and osteo-differentiation, while non-induced cells were stained negative (d.e.f). 
From presentation of “Marshak DR. Human somatic stem cell and progenitor cell systems for research 
in cell therapy, toxicity screening, and target validation”. Cambrex corporation, USA. 
(http://www.cambrex.com/content/general/sitesearch.asp?searchResponse=search&searchOperator=
and&category=ALL&searchString=stem%20%20cell)  
 
Culture medium: The PoieticsTM mesenchymal stem cell growth medium (MSCGM) 
BulletKit ® (Cambrex, Cat. No. PT-3001, USA) was applied to culture hMSCs. 
MSCGM was developed for growing large numbers of mesenchymal stem cells 
without inducing diferentiation. The MSCGM BulletKit contained one bottle of 
mesenchymal stem cell basal medium (MSCBM, Cat.No. PT-3238) and one MSCGM 
SingleQuot® Kit (Cat.No. PT-4105).  MSCBM is one 440 ml bottle of mesenchymal 
stem cell basal medium.  MSCGM SingleQuot® Kit contained mesenchymal stem 
cell growth supplement (MCGS) 50 ml, L-Glutamine 10 ml and Penicillin-Streptomycin 
0.5 ml. The MSCGM was prepared by adding of MSCGM SingleQuot® Kit into 
MSCBM before use.  
 
Culture flask: Nunc EasYFlasks™ Nunclon™Δ, Polystyrene, Sterile, T-75 (Culture 
area 75 cm²), (Nunc, Cat. No. 156499, Denmark).  
Trypsin/ ethylene diamine tetraacetic acid (EDTA) (10x) (PAA, Cat. No. L11-003, 
Austria), diluted with PBS 1:10 into 1× before use. 
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Phosphate-buffered saline (PBS) without Ca2+, Mg2+, (PAA, Cat. No. H15-002, 
Austria). 
Methods:  
Cells were seeded at 5000-6000 cells/cm2 in T-75 flasks in a humidified incubator with 
5% CO2, 37°C for subculture. Media were changed every 3-4 days. For further 
cultivation cells were trypsinized by 1× trypsin / EDTA before 40% confluence and 
reseeded.  
2.2.  Construction of pLenti6/V5-hTERT  
Material: 
human TERT cDNA: The cDNA was kindly provided within the pBABE-PURO plasmid 
by Robert Weinberg (Whitehead Institute, MIT, Boston, USA). 
Sal I (New England Biolabs, Cat. No. R0138T, USA) 
Not I (New England Biolabs, Cat. No. R0189S, USA) 
Klenow large fragment (New England Biolabs, Cat. No. M0210, USA) 
NucleoSpin Extract II kit (Machery-Nagel, Düren, Cat. No. 740609.50, Germany) 
Quick T4 ligase (Quick ligation kit) (New England Biolabs, Cat. No. M2200S, USA). 
pENTR11 vector (Invitrogen, Cat. No. 11819018, USA) 
pLenti6/V5-DEST vector (Invitrogen, Cat. No. 11819018, USA) 
TOP10 competent E.coli (Invirogen, Cat. No. C404010, USA) 
GeneElute Plamid MiniPrep Kit (Macherey-Nagel, Düren, Germany) 
LR Clonase™ II enzyme mix (Invitrogen, Cat. No. 11791-019, USA)  
One Shot® Stbl3™ chemically competent E. coli (Invitrogen, Cat. No. C7373-03, 
USA) 
QIAfilter Plasmid Midi Kit (Qiagen, Cat. No.12243, Germany) 
EndoFree Plasmid Buffer Set (Qiagen, Cat. No. 19048, Germany) 
Methods: 
Coding domain sequence of hTERT was isolated from pBABE-PURO plasmid by 
digestion with Sal I and linearized with Klenow large fragment. Therefore, 10 µg of 
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pBABE-PURO plasmid was digested for 2 hours with 20 units of Sal I in 50 µl reaction 
volume. The resulting hTERT fragment was isolated from agarose gel by NucleoSpin 
Extract II kit according to manufacturer’s protocol. Blunt ends were generated using 2 
µg of the hTERT fragment in 50 µl total volume with 10% (v/v) 10x NE Buffer2 with 8% 
(v/v) dNTP mix (10 nM) and 5 units of Klenow enzyme. After 60 min incubation at 37°C 
the reaction was stopped with the addition of EDTA (final concentration 10 mM) and 
incubation for 20 min at 75°C. The blunt end hTERT fragment was isolated by 
NucleoSpin Extract II kit.     
pENTR11 plasmid was digested with NotI and blunt ends were generated by Klenow 
large fragment. The resulting pENTR11 vector and hTERT fragment were ligated using 
Quick T4 ligase. 50 ng of vector were ligated with 3 molar excess of the insert hTERT. 
The fragments were diluted in 10 µl of water before adding 10 µl of Quick Ligation 
Buffer (2x) and 1 µl of Quick ligase, followed by a 5 min incubation period at 25°C. 5 µl 
of the reaction was used for transformation of 50 µl TOP10 competent E.coli bacteria 
were incubated on ice for 1 hour with DNA, then heat shocked for 45 sec at 42°C and 
incubated again on ice for 2 min.  250 µl of room temperature super optimized culture 
(SOC) medium was added to the bacteria and incubated at 37°C in a cell shaker for 1 
hour.  50 µl of bacterial suspension was plated on agar plates containing kanamycin. 
After overnight incubation at 37°C, colonies were isolated and grown in 5 ml of 
double-yeast-trypton (dyt)-medium overnight at 37°C. For isolation of the plasmid 
GeneElute Plamid MiniPrep Kit was used according to the manufacturer’s protocol. 
The correct colony was identified by restriction analysis.  
The coding sequence of hTERT was then transferred from pENTR11 into 
pLenti6V5-Dest by using LR Clonase reaction according to manufacturer’s protocol. 
150 ng of purified plasmid DNA of the entry clone pENTR11-hTERT and 150 ng of the 
destination vector pLenti6/V5-DEST were suspended in 8 µl TE, pH 8.0) and 2 µl of 
LR Clonase™ II enzyme mix was added. Recombination was performed at 25°C for 
60 min and stopped with 1 µl protein K solution for 10 min at 37°C. 2 µl of the reaction 
was transformed with the standard protocol (see above) in One shot Stbl3 competent 
E.coli. After identification of the correct clone by restriction analysis and mini 
preparation, larger amounts of plasmid DNA pLenti6/V5-hTERT was generated with 
endotoxin-free Midi Prep Kit according to the manufacturer’s protocol. To confirm that 
the gene of interest (hTERT) was correctly transferred into pLenti6V5-Dest vector, 
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expression construct of pLenti6V5-hTERT was sequenced afterwards for inserted 
hTERT gene.       
2.3.  Producing lentivirus in 293FT cells in T-225 flask 
Material: 
ViralPowerTM Lentiviral Expression System (Cat. No. K4960-00): 
ViralPowerTM Blasticidin Lentiviral Support Kit:  
ViralPowerTM Packaging Mix (pLP1, pLP2 and pLP/VSVG plasmids) (1μg/μl) 
LipofectamineTM 2000 Reagent (4°C). 
Blasticidin (concentration). 
pLenti6/V5-DEST Gateway® Vector Kit:  
pLenti6/V5-DEST Vector ( μg/μl, endotoxin free) 
One Shot® Stbl3™ Chemically Competent E. coli 
293FT cells （Invitrogen, Cat. No. R700-07, USA） 
T-225 tissue culture flask (Nunclon, Cat.No.159934, Denmark) 
Opti-MEM® I reduced serum medium （Invitrogen, Cat. No. 31985-070, USA） 
Fetal bovine medium (FBS) (Sigma, Cat. No. 103K3395, USA) 
Lipofectamine™ 2000（Invitrogen, Cat. No. 11668-019, USA） 
50ml sterile, capped, conical tubes (Sarstedt, Cat. No. 62.547.254, Germany) 
Polybrene (Sigma, Cat. No. H9268, USA) 
HT1080 (ATCC, Cat. No.CCL-121, USA) 
Blasticidin (Invitrogen, R210-01, USA) 
Crystal violet (Sigma, Cat. No. C3886, USA)  
Methods: 
For generation of lentivirus the ViralPowerTM Lentiviral Expression System was used 
with some minor modifications. For lentivirus production 293FT cells (cultured not 
more than 20 passages in vitro) were used. On day 1 293FT cells were plated in 10 ml 
of growth medium containing serum in a T-225 flask without antibiotics. On day 2 cells 
were trypsinized and counted. 1.2×106 cells/ml 293FT cells were resuspended in 
Opti-MEM® I medium containing 10% FBS but no antibiotic. For each transfection 
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sample DNA-Lipofectamine™ 2000 complexes were prepared as follows: in a sterile 
14 ml tube 35.7 μg of the ViraPower™ Packaging Mix were diluted with 11.9 μg of 
pLenti6/V5-hTERT in 5.9 ml of Opti-MEM® I Medium without serum. In a separate 
sterile 14 ml tube 142.8 μl Lipofectamine™ 2000 was mixed gently with 5.9 ml of 
Opti-MEM® I Medium without serum and incubate for 5 minutes at room temperature. 
After 5 minutes of incubation, the diluted DNA was combined with the diluted 
Lipofectamine™ 2000 and incubated for 20 minutes at room temperature to allow the 
DNA-Lipofectamine 2000 complexes to form. The DNA-Lipofectamine™ 2000 
complexes were added to a T-225 tissue culture flask containing 19.8 ml Opti-MEM® I 
medium with serum but without antibiotics. Then 19.8 ml of the 293FT cell suspension 
(23.76×106 total cells) was added to the flask containing media and 
DNA-Lipofectamine™ 2000 complexes. The cells were incubated overnight at 37°C in 
a humidified 5% CO2 incubator. After 6 hours of incubation, the medium containing 
the DNA-Lipofectamine was removed and replace with 21 ml complete culture 
medium without antibiotics. Virus-containing supernatants were harvested 45 hours 
posttransfection by removing medium into to a 50 ml sterile, capped, conical tube. The 
supernatants were centrifuged at 3000 rpm for 15 minutes at +4°C to pellet debris. 
The collected viral supernatant was stored at -80°C until further use.  
To determine the titer of lentiviral stocks, a kill curve experiment was performed to 
determine the minimum concentration of Blasticidin required killing non-transduced 
mammalian cell line within 14 days after addition of antibiotic. A 10-fold serial dilution 
was prepared from lentiviral stocks. The different dilutions (serial dilutions ranging 
from 10-2 to 10-6) of hTERT-lentivirus were transduced into HT1080 in the presence of 
the polycation Polybrene®. The stably transduced cells were select by using 
Blasticidin. The cell culture plates were stained by 1% crystal violet and the number of 
Blasticidin-resistant colonies was counted in each dilution. The titer of the lentiviral 
stocks were calculated as: (Σ (Number of colonies) x 10n)/ Σ (Number of plates) 
transducing units (TU)/ml. 
2.4.  Transduction and Analysis 
hMSCs were transduced with pLenti6/V5-hTERT (Titer: 5 x 104 TU/ml) at 5th passage 
using 6 µg/ml Polybrene. Successfully transduced hMSCs were selected with 10 
µg/ml Blasticidin for 10 days. Expression of hTERT was confirmed by RT-PCR.  
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2.4.1 RNA extraction 
Material: 
Cells: Cells were harvested at around 10th passage at initial stage and around 40th 
passage. Samples were listed as below in this thesis: 
hMSCs hTERT-transduced hMSCs-hTERT 
hMSCs hTERT-transduced, heterogeneous TERT 
hMSCs hTERT-transduced, single cell picking clone SCP 1,9,11,12 
hMSCs non-transduced hMSCs 
TERT-10 Passage (10P), SCP1-9P, SCP9-8P, SCP12-9P, hMSCs-11P 
TERT-44P, SCP1-42P, SCP9-35P, SCP11-45P, SCP12-46P, hMSCs-5P  
RNeasy® Mini Kit (Qiagen, Cat. No.74106, Germany): 
RNeasy Mini Spin Columns  
Collection Tubes (1.5 ml)  
Collection Tubes (2 ml)  
Buffer RLT  
Buffer RW1 
Buffer RPE  
RNase-Free Water 
β-mercaptoethanol (β -ME) (Sigma, Cat. No.M7522, USA) 
Ethanol (Merck KGaA, Cat. No.818760, Germany) 
QIAshredder spin column (Qiagen, Cat. No. 79656, Germany). 
 
Methods: 
Total RNA was extracted respectively from cell culture using RNeasy® Mini Kit. 
Ⅰ. Pre-preparation: 
Added 10 μl β -ME per 1 ml Buffer RLT (Dispensed in a fume hood and wore 
appropriate protective clothing.)  
Buffer RPE was a concentrate. Before using for the first time, added 4 volumes of 
ethanol (96–100%) as indicated on the bottle to obtain a working solution. 
Ⅱ. Harvesting cells:   
Aspirated the medium, and washed the cells with PBS, aspirated the PBS, and 
added 1× trypsin/EDTA. After the cells detached from the dish or flask, added 
medium (containing serum to inactivate the trypsin), transfered the cells to an 
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RNase-free polypropylene centrifuge tube, and centrifuged at 300 x g for 5 min 
Completely aspirated the supernatant. 
Ⅲ. Disrupting the cells: 
Loosened the cell pellet thoroughly by flicking the tube. Added 350 μl of Buffer RLT, 
pipetted to mix. 
Ⅳ. Homogenized the lysate: 
Pipetted the lysate directly into a QIAshredder spin column placed in a 2 ml 
collection tube, and centrifuged for 2 min at full speed.  
Ⅴ. Added 1 volume of 70% ethanol to the homogenized lysate, and mixed well by 
pipetting. 
Ⅵ. Transfered up to 700 μl of the sample to an RNeasy spin column placed in a 2 ml 
collection tube, centrifuged for 15 s at ~8000 x g (~10,000 rpm). Discarded the 
flow-through. 
Ⅶ. Added 700 μl Buffer RW1 to the RNeasy spin column, centrifuged for 15 s at 
~8000 x g (~10,000 rpm) to wash the spin column membrane. Discarded the 
flow-through. 
Ⅷ. Added 500 μl Buffer RPE to the RNeasy spin column, centrifuged for 15 s at 
~8000 x g (~10,000 rpm) to wash the spin column membrane. Discarded the 
flow-through. 
Ⅸ. Added 500 μl Buffer RPE to the RNeasy spin column, centrifuged for 2 min at 
~8000 x g (~10,000 rpm) to wash the spin column membrane. 
Ⅹ. Placed the RNeasy spin column in a new 2 ml collection tube, centrifuged at full 
speed for 1 min 
Ⅺ. Placed the RNeasy spin column in a new 1.5 ml collection tube, added 30μl 
RNase-free water directly to the spin column membrane, centrifuged for 1 min at 
~8000 x g (~10,000 rpm) to elute the RNA. 
2.4.2 Reverse transcription of RNA into cDNA 
1μg of RNA was transformed into cDNA using AMV first-strand cDNA synthesis kit 
(Invitrogen, USA). 
 
Material: 
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RNA (1μg) from above sample. 
Cloned AMV First-Strand cDNA Synthesis Kit (Invitrogen, Cat. No. 12328-040, USA) 
Cloned AMV RT (15 U/µl) 
5X cDNA Synthesis Buffer*  
0.1 M DTT  
10 mM dNTP Mix  
RNaseOUT. (40 U/µl)  
Oligo (dT)20 (50 µM)  
Random Hexamers (50 ng/µl)  
DEPC-Treated Water  
MultiCycler (MJ Research, Cat. No. PTC200, USA) 
 
Methods: 
Ⅰ. In a 0.2 ml tube, combined 50 ng/µl random primer, RNA, and dNTP mix. Adjusted 
the volume to 12 µl with DEPC-treated water. 
Primer 1 µl 
RNA (1μg) x µl (different volume according to concentration) 
10 mM dNTP Mix 2 µl 
DEPC-treated water to 12 µl 
Ⅱ. Denatured the RNA and primers by incubating at 65°C for 5 min and then placed 
on ice. 
Ⅲ. Vortexed the 5X cDNA Synthesis Buffer for 5 sec. 
Ⅳ. Prepared the following master reaction mix on ice and vortex gently. 
5x cDNA Synthesis Buffer 4 µl 
0.1 M DTT 1 µl 
RNaseOUT. (40 U/µl) 1 µl  
DEPC-treated water 1 µl 
Cloned AMV RT(15 units/µl) 1 µl 
(Total Volume) 8 µl 
Ⅴ. Pipetted 8 µl of the master reaction mix into each reaction tube on ice. 
Ⅵ. Transfered the reaction tube to the MultiCycler. Incubated at 25°C for 10 min, 
followed by 20-50 min at 50°C 
Ⅶ. Terminated the reaction by incubating at 85°C for 5 min 
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2.4.3 Detection of the hTERT gene expression by polymerase chain reaction (PCR) 
 
The hTERT gene at mRNA level was detected by PCR using Taq polymerase with the 
amplification of β-actin as control.  
 
Material: 
Taq DNA Polymerase, recombinant (Invitrogen, Cat. No. 10342-053, USA) 
10X PCR Buffer, Minus Mg2+ 
50 mM Magnesium Chloride (MgCl2) 
Primers of hTERT: 
(Forward) 5’-CTACGGCGACATGGAGAAC-3’, 
(Reverse) 5’-GACACTTCAGCCGCAAGAC-3’  
Primers for β-actin:  
(Forward) 5’-GCACTCTTCCAGCCTTCC-3’ 
(Reverse) 5’-AGAAAGGGTGTAACGCAACTAAG-3’ (Synthesized by Invitrogen). 
 
Methods: 
Ⅰ. Added the following components to a sterile 0.5-ml microcentrifuge tube sitting on 
ice(Prepared master mix for multiple reactions): 
 
10X PCR buffer, minus Mg 2 μl (1X) 
10 mM dNTP mixture 0.4 μl (0.2 mM each) 
50 mM MgCl2 0.6 μl (1.5 mM) 
Primer mix (10 μM each) 1 μl (0.5 μM each) 
Template DNA 1–20 μl 
Taq Polymerase (5 U/μl) 0.2μl (1.0 unit) 
Autoclaved distilled water to 20 μl 
 
Ⅱ. Mixed contents of tube. 
Ⅲ. Caped tubes and centrifuged briefly to collect the contents to the bottom. 
Ⅳ. Perform PCR amplification as follows: 
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PCR programm: β-actin 
Step T (C°) time Repeats 
1. Predenaturation 95 3 min   
2. Denaturation 95 1 min 
25x 3. Annealing  55 1 min 
4. Extension 72 1 min 
5. Final extension 72 10 min   
6. 4 for ever   
7. end     
Expected size of the amplified band bp 
β-actin 385 
 
PCR programm: hTERT 
Step T (C°) time Repeats 
1. Predenaturation 95 10min   
Hotstart 
2. Denaturation 95 30sec   
35x 
  
3. Annealing  54 30sec 
4. Extension 72 1min 
5. Final extension 72 10 min   
6. 4 for ever   
7. end     
Expected size of the amplified band bp 
hTERT  413 
 
Ⅴ. Analyzed the amplification products by 1% agarose gel electrophoresis and 
visualized by ethidium bromide staining. Used 100 bp DNA molecular weight 
standards. 
2.5.  Single cell picking  
Single cell was picked by limited dilution at 7th passage and expanded into 
single-cell-picking clone (SCP). Of 22 single-cell-picking clones, SCP1, SCP9, SCP11 
and SCP12 were continuously passaged and compared with heterogeneous 
hTERT-transduced hMSCs and non-transduced hMSCs. 
 
Material: 
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Petri dish 100 x 20mm (Falcon, Cat. No. 353003, USA) 
6-well-plate (Nunclon, Cat. No140675, Denmark) 
10 µl Pipette tips (Diamond D10 Easy Pack 1000) (Gilson, Cat. No. F 161631, France) 
 
Methods: 
Ⅰ. Seeded cells at 75 cells / cm² in T-25 flask or 5000 cells in the 100 x 20mm Petri 
dish 4-5 days earlier before single cell picking. 
Ⅱ. Pipetted 100 µl medium drop in each well of 6-Well-plate (Field A1 empty for 
control). 
Ⅲ. Trypsinized cells about 3 min and picked them up in 5 ml medium. 
Ⅳ. Diluted the above cell suspension to 1:10 in a 15 ml falcon tube (i.e. 1 ml cell 
solution and 9 ml PBS). 
Ⅴ. Pipetted 5 ml of the dilution in a Petri dish. 
Ⅵ. Out of the flow, picked one cell with a 10 µl Pipette (positioned to 3 µl) and pipetted 
the cell into the drop of the medium (If it was not possible to pick single cell, diluted 
the cell suspension further). 
Ⅶ. Into the flow, pipetted 2 ml of the cell suspension in control well-A1. 
Ⅷ. Pipetted 2 ml of medium into each well after 2-4 hours. 
Ⅸ. Documented the result by making pictures under microscope with digital camera. 
2.6.  Proliferation assay  
2.6.1 Morphological observation 
Cells of non-transduced, clonal and heterogeneous hTERT-transduced hMSCs were 
continuously passaged. Cells were observed and photographed under phase contrast 
microscope (Axiovert S100, Carl Zeiss, Germany) to check and document the 
morphology of cells.  
2.6.2 Cumulative population doubling level (PDL) and population doubling time (PDT) 
Long-term cell growth in vitro was monitored by cell number count and PDL and PDT 
calculation. Before 40% confluence, cells were trypsinized by 1× trypsin / EDTA, 
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stained by trypan blue and counted by a hemocytometer.  Trypan blue was a vital 
diazo dye that was used to color dead tissues or cells blue. Live cells or tissues with 
intact cell membranes would not be colored. Since cells were very selective in the 
compounds that passed through the membrane, trypan blue was not absorbed in a 
viable cell; however, it traversed the membrane in a dead cell. Hence, dead cells were 
shown as a distinctive blue colour under a microscope. So this staining method was 
used to discern live cells from dead cells in counting. 
 
Material: 
Hemocytometer (Improved Neubauer, Superior Ltd, Germany) 
0.4% Trypan blue (Gibco, Cat. No. 15250-061, USA) 
Invert Microscope (Diavert, Leitz Wetzlar, Germany) 
 
Methods: 
Ⅰ. Trypsinized cells and resuspended in definite volume (V) of medium under laminar 
air flow hood; 
Ⅱ. Collected 50 - 100 µl cells suspension in one 1.5 ml microfuge tube; 
Ⅲ. Put 10 µl cell suspension and 5 µl trypan blue into a new microfuge tube and 
mixed; 
Ⅳ. Put one drop (5-8 µl) of trypan blue/cell suspension mixture under the cover glass 
on the hemocytometer; 
 
 
 
Figure 3. Cell suspension was put under the cover glass on the hemocytometer 
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Ⅴ. Counted Cells under 10 x object lens. Only non-blue-stained cells were counted. 
Cell number in the area of A, B, C, D and on the upper and left border of A, B, C, D 
were added together. 
 
 
Figure 4. Cell counting area of the hemocytometer   
 
Cell number = ((A+B+C+D)/4) × 1.5 × V (V: cell suspension volume) 
 
Ⅵ . Population doubling was used to describe cell growth in logarithmic mode, 
population doubling gained at each passage was determined using the formula 
below: 
PD = (log (N n / N 0)) / log 2, or 
PD = (log (N n / N 0)) X 3.33 
N n = Number of cells harvested at the end of a period of growth; 
N 0 = Number of cells plated initially in the growth vessel. 
Cumulative population doubling level (PDL) was thus the sum of population 
doublings: 
PDLn = Σ PD (1, n) (n: Number of passage) 
 
Ⅶ. Population doubling time (PDT, also called the generation time), was the period of 
time required for cell number to double. To calculate PDT, the time period for the 
cells to growth was divided by the population doubling value which was gained in 
the same time period. The formula was as below: 
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PDT = Time period (day) / PD 
Both PDL and PDT were used to evaluate and compare the growth rate of 
hTERT-transduced and non-transduced hMSCs.  
2.7.  Senescence-associated β-gal staining 
The cellular senescence process was associated with aging. The decrease in cell 
division was virtually irreversible and complete. In conjunction with the loss of the 
ability to divide, changes occurred in the morphology and in their pattern of gene 
expression of the cells. At the end of the senescence cell death usually occurred, 
although the cells might remain viable for a long time. The senescent cells staining 
assay was based on a histochemical stain for β-galactosidase activity at pH 6. Under 
these conditions, β-galactosidase activity was easily detectable in senescent cells, but 
undetectable in quiescent, immortal, or tumor cells. In the experiment, hMSCs, 
non-transduced, clonal and heterogeneous hTERT-transduced, were cultured in 
6-well plates and stained by senescence cells histochemical staining kit. 
 
Material: 
Senescent cells staining kit (Sigma, Cat. No. CS0030, USA) 
Fixation buffer 10X (Product Code F 1797) solution containing 20% formaldehyde, 
2% glutaraldehyde, 70.4 mM Na2HPO4, 14.7 mM KH2PO4, 1.37 M NaCl, and 26.8 
mM KCl; 
Reagent B (Product Code R 5272) 400 mM Potassium Ferricyanide; 
Reagent C (Product Code R 5147) 400 mM Potassium Ferrocyanide; 
X-gal solution (Product Code X 3753) 40 mg/ml. 
Ultra pure water (Sigma, Cat. No. W4502-1L, USA) 
6-well-plate (Nunclon, Cat. No. 140675, Denmark) 
 
Methods: 
Ⅰ. Preparation of staining solution: 
The amounts of reagents detailed in the procedure were for 6 tests performed on 35 
mm plates. For plates/wells of different sizes, calculated the volumes of the 
reagents required according to the table: 
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Plate 
Well diameter 
(mm) 
Growth area (cm2) 
Volume relative to 
35 mm plate 
100mm 100.00 78.50 8.26 × 
60mm 60.00 30.00 3.15 × 
35mm 35.00 9.50 1 × 
6 well 34.80 9.50 1 × 
12 well 22.10 3.80 0.4 × 
24 well 15.60 1.90 0.2 × 
96 well 6.40 0.32 0.034 × 
 
X-gal solution: warmed the X-gal solution at 37 °C for 1 hour.  
Fixation buffer 1X: diluted the fixation buffer 10X 10-fold with ultra pure water.  
PBS 1X: diluted the PBS 10X 10-fold with ultra pure water.  
Staining mixture (Prepared just prior to use): mixed the following for preparation of 
10 ml of the staining mixture: 
Staining solution 10X 1 ml 
Reagent B 125 μl 
Reagent C 125 μl 
X-gal solution 0.25 ml 
Ultra pure water 8.50 ml 
Filtered the staining mixture using a 0.2 mm filter to ensure there were no 
aggregates in the solution (very important!). 
Ⅱ. Procedure of staining: 
Aspirated the growth medium from the cells. 
Washed the cells twice with 1 ml of 1X PBS per well/plate. Carefully removed the 
entire wash solution by aspiration, so the cells did not detach. 
Added 1.5 ml per well of 1X fixation buffer and incubated the plate for 6–7 minutes 
at room temperature. 
Rinsed the cells 3 times with 1 ml of 1X PBS per well/plate. 
Added 1 ml of the staining mixture per well. 
Incubated at 37 °C without CO2 for 12 hours until the cells were stained blue. 
Sealed the plate with Parafilm to prevent it from drying out. Checked the pH value 
before sealing the plate, adjusted the pH value to 6 with HCl or NaOH when it was 
not the right pH value. 
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After staining the staining mixture was replaced with 1X PBS. The cells were 
observed under a microscope and photos were taken. 
2.8.  Differentiation assay 
Clonal and heterogeneous hTERT-transduced hMSCs were induced at different 
passages (SCP1-47th Passage, SCP11-68th Passage, TERT-52nd Passage) into three 
mesodermal lineages by lineage-specific medium.  
 
2.8.1. Adipogenic differentiation.  
2.8.1.1. Adipogenic induction: 
Material: 
Medium: DMEM + 4500 mg/L Glucose + GlutaMAX I + Pyruvat (PAA, Cat. No. 
E15-843, Austria) 
Fetal bovine serum (FBS), heat inactivated (Sigma, Cat. No. 103K3395, USA)  
Penicillin/Streptomycin (Gibco, Cat. No. 1202798, USA) 
Dexamethasone (Sigma, Cat. No. D-2915, USA) 
Indomethacin (Sigma, Cat. No. I-5879, USA) 
Insulin (Sigma, Cat. No. I-0516, USA) 
3-Isobutyl-1-methylxanthin (IBMX) (Sigma, Cat. No. I-7378, USA) 
 
Methods: 
Ⅰ. Prepared medium for induction according to the chart below: 
Substance 
Concentration in 
stock solution 
Concentration in 
medium 
Amount 
Medium DMEM h-g   8600 µl 
FBS 100 % 10 % 1000 µl 
Penicillin/Streptomycin 10000 IU/ml 40 IU/ml 40 µl 
Dexamethasone 50 µM 1 µM 200 µl 
Indomethacin 50 mM 0,2 mM 40 µl 
Insulin 10 mg/ml 0,1 mg/ml 100 µl 
IBMX 500 mM 1 mM 20 µl 
   10000 µl 
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Ⅱ. Prepared medium for conservation according to the chart below: 
Substance 
Concentration in 
stock solution 
Concentration in 
medium 
Amount 
Medium DMEM h-g   8900 µl 
FBS 100 % 10 % 1000 µl 
Penicillin/Streptomycin 10000 IU/ml 40 IU/ml 40 µl 
Insulin 10 mg/ml 0,1 mg/ml 100 µl 
   10040 µl 
 
Ⅲ. Counted the cells.  
Ⅳ. Plated the cells in a concentration of 10000 cells/cm2. 
Ⅴ. Started the differentiation at total confluence. 
Ⅵ. Used induction medium for 5 days and conservation medium for 2 days. 
Ⅶ. Differentiated cells for 21 days. 
 
2.8.1.2. Adipogenic staning: 
After adipogenic differentiation, cells in well-plate were stained by Oil red O for 
intracellular fat droplets. 
 
Material: 
Oil red O (Sigma, Cat. No. O-0625, USA) 
Isopropanol (Merck KGaA, Cat. No.1.09634.2500, Germany) 
Distilled water (dH2O) 
4 % Formaldehyde solution, neutralized (Fischar GmbH, Cat. No. 6333115, Germany) 
Filter Whatmann 42 (Herolab GmbH, Laborgeräte Wieloch, Germany)  
50 % Ethanol (Merck KGaA, Cat. No.818760, Germany) 
 
Methods: 
Ⅰ. Prepared Oil red O staining solution. 
0.3% Oil red O stock solution: 
Diluted 150 mg Oil red O in 50 ml Isopropanol, mixed for 10 min with stirrer (Stable 
for use within one month). 
0.2% Oil red O working solution: 
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Mixed 12 ml stock solution with 8 ml dH2O, stood on bench for 10 min, filtered with 
Filter Whatman 42 (Stable for use within 3 hours). 
Ⅱ. Aspirated culture medium. 
Ⅲ. Fixed cells with pre-colded 4 % formaldehyde for 2 min at –20°C. 
Ⅳ. Washed with pre-colded 50% ethanol. 
Ⅴ. Stained cells with 0.2% Oil red O Working solution for 20 min 
Ⅵ. Washed with 50% ethanol. 
Ⅶ. Washed with dH2O for 1 min with shaking. 
Ⅷ. Observed under microscope. Positive cells were stained strong orange or red in 
the cytoplasm.  
 
 
2.8.2. Chondrogenic differentiation.  
 
2.8.2.1. Chondrogenic induction: 
 
Material: 
Medium: DMEM + 4500 mg/L Glucose + GlutaMAX I + Pyruvat (PAA, Cat. No. 
E15-843, Austria) 
Penicillin/Streptomycin (Gibco, Cat. No. 1202798, USA) 
Dexamethasone (Sigma, Cat. No. D-2915, USA)  
Sodium pyruvate (Sigma, Cat. No.: S-8636, USA) 
L– Ascorbic acid (Sigma, Cat. No. A-8960, USA) 
L-Proline (Sigma, Cat. No.: P-5607, USA) 
ITS 100x (Sigma, Cat. No.: I-3146, USA) 
Linoleic acid (Sigma, Cat. No.: L5900, USA) 
Bovine serum albumin (BSA) (Sigma, Cat. No.: A-9418, USA) 
15mL polypropylene tube (Sarstedt, Cat. No. 62.554.502 ,Germany) 
Recombinant human transforming growth factor-β3 (TGF-β3) (R & D Systems, Cat. 
No. 243-B3, USA), 
 
Methods: 
Ⅰ. Prepared the incomplete medium according to the chart below: 
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Substance 
Concentration in 
stock solution 
Concentration in 
medium 
Amount 
Medium DMEM h-g   47100 µl 
Penicillin/Streptomycin  10000 IU/ml 40 IU/ml 200 µl  
Dexamethasone 50 µM 0,1 µM 100 µl 
Sodium pyruvate  100 mM 1 mM 500 µl 
L– Ascorbic acid 12,5 mM 0,195 mM (50µg/ml) 780 µl 
L-Proline 175 mM 0,35 mM 100 µl 
ITS 100x 
6,25 µg/ml Insulin 
6,25 µg/ml transferrin 
6,25 ng/ml Selenite 
625 µl 
Linoleic acid 2,677 mg/ml (500x) 5,35 µg/ml 100 µl 
BSA 125 mg/ml 1,25 mg/ml 500 µl 
   50005 µl  
 
Ⅱ. Added 1 µl TGF-β3 to 2 ml incomplete medium to establish complete medium with 
the final concentration of TGF-β3 was 10ng/ml. 
Ⅲ. Trypsinized and harvested the cells by 1× trypsin/EDTA. 
Ⅳ. Counted the cells (200000 cells were needed for one pellet). 
Ⅴ. Transfered the cell-suspension into a 15 ml tube.  
Ⅵ. Centrifuged the cells at 150g, RT for 5min, and evacuated the medium. 
Ⅶ. Resuspended the cells in 1 ml incomplete medium (control pellet with normal 
DMEM medium). 
Ⅷ. Centrifuged the cells and evacuated the medium. 
Ⅸ. Resuspended the cells in 1 ml complete medium (control pellet with normal 
medium). 
Ⅹ. Centrifuged the cells (Did not evacuate the medium). 
Ⅺ. Untwisted the cap of the tube for incubation in the incubator. 
Ⅻ. Incubated the pellets (Did not take the tubes out of the incubator in the first 24 
hours). After 24 hours the pellet should swim in the medium. 
XIII. Changed the medium every two to three days (Did not aspirate the pellet). 
XIV. Flipped the tube carefully after changing the medium to relieve the pellet from the 
wall of the tube. 
XV. Control pellets were cultured with DMEM.  
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XVI. The pellets were fixed and sectioned for toluidine blue staining after 5 weeks.  
 
2.8.2.2. Chondrogenic staining: 
Toluidine blue staining was employed to stain proteoglycan that was formed during 
chondrogenic differentiation. Extracellular proteoglycan formation was stained bright 
blue during chondrogenesis.  
 
Material: 
Toluidine blue O (Merck KGaA, Cat. No. 52040, Germany) 
 
Methods: 
Ⅰ. Prepared 1% Toluidine blue stain: 
Weighed toluidine blue 1g and natrium tetraborate 1g, diluted them in 100ml dH2O, 
filtered twice with filter paper.  
Ⅱ. Stained section slides with 1% Toluidine blue for 1 min 
Ⅲ. Washed slides with tap water for 120 min (Changed water every 20 min until no 
stain would be washed off from the slides). 
Ⅳ. Mounted the 6-well-plates with Di-n-butylPhthalate in Xylene (DPX), took photos 
under microscope. 
 
2.8.3. Osteogenic differentiation.  
2.8.3.1. Osteogenic induction: 
Material: 
Medium: DMEM + 4500 mg/L Glucose + GlutaMAX I + Pyruvat (PAA, Cat. No. 
E15-843, Austria) 
Fetal bovine serum (FBS), heat inactivated (Sigma, cat. No. 103K3395, USA) 
Penicillin/Streptomycin (Gibco, Cat. No. 1202798, USA) 
Dexamethasone (Sigma, Cat. No. D-2915, USA)  
β- Glycerophosphate (Sigma, Cat. No. G-9891, USA) 
L– Ascorbic acid (Sigma, Cat. No. A-8960, USA) 
 
Methods: 
Ⅰ. Prepared the osteogenic differentiation medium according to the chart below:  
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Substance 
Concentration in stock 
solution 
Concentration in 
medium 
Amount 
Medium DMEM h-g   22100 µl 
FBS 100 % 10 % (v/v) 2500 µl  
Penicillin/Streptomycin  10000 IU/ml 40 IU/ml 100 µl  
Dexamethasone 50 µM 100 nM 50 µl 
β – Glycerophosphate 1.66 M 10 mM 151 µl 
L – Ascorbic acid 12.5 mM 50 µM 100 µl 
   25001 µl 
 
Ⅱ. Trypsinized and counted cells. 
Ⅲ. Seeded cells at 4000 – 5000 cells / cm2 in 6-well plates. 
Ⅳ. Started differentiation at 70% - 80% confluence (24h – 48h after seeding) 
Ⅴ. Changed medium twice a week (Inducing medium could be used in 4 weeks after 
preparation); 
Ⅵ. Induced cells for 21 days. 
Ⅶ. Control cells were cultured without inducing supplements.  
 
2.8.3.2. Osteogenic staining: 
Cells in well-plates were stained by van Kossa reagents and photographed under 
invert microscope. Von Kossa staining was applied for demonstrating deposits of 
extracellular calcium or calcium salt. In this method, tissue or cell culture were treated 
with a silver nitrate solution and the silver was deposited by replacing the calcium 
reduced by the strong light, and thereby visualized as metallic silver. 
 
Material: 
Methanol (Aldrich, Cat. No. 49443-7, USA) 
Distilled water (dH2O) 
5% Silver Nitrate (AgNO3) solution (Carl Roth GmbH, Cat. No. 7908.1, Germany) 
1% Pyrogallol solution (Apotheke innenstadt Uni München, Cat. No. P0121, 
Germany) 
5% Sodium hydroxide (NaOH) (MercK KGaA, Cat. No. B948769 301, Germany)  
Tap water 
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May-Grünwald’s esosine-methylene blue solution modified (Merck KGaA, Cat. No. 
OB486153, Germany) 
 
Methods: 
Ⅰ. Fixed cells with methanol for 15 min 
Ⅱ. Washed with dH2O for 20 min  
Ⅲ. Stained with 5% AgNO3 for 20 min at dark place. 
Ⅳ. Washed with dH2O for 3 min, twice. 
Ⅴ. Stained with 1 % pyrogallol for 5 min to demonstrate cytoplasm. 
Ⅵ. Washed with dH2O for 3 min 
Ⅶ. Fixed with 5% NaOH for 4 min 
Ⅷ. Washed with tap water carefully for 3 min, twice. 
Ⅸ. Washed with dH2O. 
Ⅹ. Stained with May-Grünwald’s esosine-methylene blue solution modified for 10 min 
to demonstrate cell nucleus. 
Ⅺ. Washed with dH2O. 
Ⅻ. Took photos under microscope, sealed well-plate with Parafilm and stored. 
XIII. Staining result: Calcified region-dark black, cell nucleus-blue, cytoplasm-red. 
2.9.  Karyotype (cytogenetics) analysis 
Cytogenetics studies were performed on metaphase cells derived from clonal 
hMSCs-hTERT SCP1 at 92nd passage, SCP11 at 89th passage and SCP12 at 80th 
passage.  Harvesting and fixation followed standard protocols. Chromosome 
analysis was performed using the GTG-banding technique with a 400 bphs resolution. 
Fifteen metaphases captured by a CCD-camera were analysed and karyotyped using 
a karyotyping software. Chromosome identification and karyotype description were 
made in accordance with the International System for Chromosome Nomenclature. 
 
To investigate whether the identified deletion found in cytogenetics analysis already 
pre-existed, two-colour fluorescence in situ hybridization （FISH）was performed on 
hTERT-hMSCs (passage 11) and hMSC (passage 12) using subtelomeric probes 
16PTER and 16QTER (Abbott Diagnostics, Wiesbaden, Germany). The 
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16PTER-probe was labelled in green (SpectrumGreen) and the 16QTER-probe in red 
(SpectrumOrange). Hybridization solution and probes were mixed 1:1 (followed 
manufacturer’s protocols), dropped onto chromosome slides and covered. 
Co-denaturation of the slides was performed at 73°C for 2 min. followed by incubation 
at 37°C in a humidified chamber over night. After hybridization, the slides were 
washed following probe protocols and mounted in vectrashield mounting medium for 
fluorescence with DAPI (4’,6-diamino-2-phenylindole) (Linaris, Wertheim, Germany). 
Fluorescence signals were observed with a Zeiss fluorescence microscope. A total of 
198 interphase nuclei were analyzed. 
2.10.  Tumor suppressor gene assay 
RNA from different passages of clonal, heterogeneous hTERT-transduced and 
non-tranduced hMSCs were extracted respectively and checked for the expression of 
the tumor suppressor genes —retinoblastoma 1 (RB1),  tumor protein 53 (TP53) and 
cyclin-dependent kinase inhibitor 1A (CDKN1A, p21) by polymerase chain reaction 
(PCR).  
 
Material: 
Cells:  
Initial period: SCP1-9 P, SCP9-8P, SCP11-13P, SCP12-9P, TERT-10P. 
Plateau period: SCP1-42P, SCP9-35P, SCP11-45P, SCP12-46P, TERT-44P 
Rapid-growing period: SCP1-62P, SCP11-63P 
Non-transduced hMSCs-5P, MG63 (osteosarcoma cell line) were employed as 
control. 
RNeasy® Mini Kit (Qiagen, Cat. No.74106, Germany). 
Cloned AMV First-Strand cDNA Synthesis Kit (Invitrogen, Cat. No. 12328-040, USA) 
Taq polymerase (Invitrogen, Cat. No. 10342-053, USA) 
Primers (Synthesized by invitrogen): 
Primers of RB1: 
(Forward) 5’-TTTCAGAAGGTCTGCCAACACCAA-3’, 
(Reverse) 5’-GTGTCCACCAAGGTCCTGAGATCC-3’  
Primers of TP53: 
(Forward) 5’- AAGGAAATTTGCGTGTGGAG-3’ 
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(Reverse) 5’- TTCTGACGCACACCTATTGC-3’ 
Primers of p21: 
(Forward) 5’-GAACTTCGACTTTGTCACCGAG-3’ 
(Reverse) 5’-CGTTTTCGACCCTGAGAGTCTC-3’ 
Primers for β-actin (internal control):  
(Forward) 5’-GCACTCTTCCAGCCTTCC-3’ 
(Reverse) 5’-AGAAAGGGTGTAACGCAACTAAG-3’ 
 
Methods: 
Ⅰ. Extracted RNA from cells by RNeasy® Mini Kit. 
Ⅱ. Reverse transcriptized RNA into cDNA by AMV first-strand cDNA synthesis kit. 
Ⅲ. Detected RB1, TP53 and p21 gene expression by PCR using Taq polymerase, 
with the amplification of β-actin as control.  
Ⅳ. Performed PCR amplification as follows: 
 
PCR programm: RB1 
Step T (C°) time Repeats 
1. Predenaturation 95 5 min   
2. Denaturation 94 1 min 
35x 3. Annealing  58 1 min 
4. Extension 72 1 min 
5. Final extension 72 10 min   
6. 4 for ever   
7. end     
Expected size of the amplified band bp 
RB1 368 
 
 PCR programm: TP53 
Step T (C°) time Repeats 
1. Predenaturation 95 5 min   
2. Denaturation 95 45 sec 
32x 3. Annealing  58 45 sec 
4. Extension 72 1 min 
5. Final extension 72 5 min   
6. 4 for ever   
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7. end     
Expected size of the amplified band bp 
TP53 702 
 
 
PCR programm: p21 
Step T (C°) time Repeats 
1. Predenaturation 94 1 min   
2. Denaturation 92 30 sec 
30x 3. Annealing  60 30 sec 
4. Extension 75 90 sec 
5. Final extension 72 10 min   
6. 4 for ever   
7. end     
Expected size of the amplified band bp 
p21 279 
 
PCR programm: β-actin 
Step T (C°) time Repeats 
1. Predenaturation 95 3 min   
2. Denaturation 95 1 min 
25x 3. Annealing  55 1 min 
4. Extension 72 1 min 
5. Final extension 72 10 min   
6. 4 for ever   
7. end     
Expected size of the amplified band bp 
β-actin 385 
 
Ⅴ. Analyzed the amplification products by 1% agarose gel electrophoresis and 
visualized by ethidium bromide staining. Used 100 bp DNA molecular weight 
standards. 
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2.11.  Cell transformation soft agar assay 
Test principle 
Neoplastic cell transformation resulted from the accumulation of genetic mutations 
that permitted uncontrolled proliferation and independence from normal homeostatic 
regulation. Cell changes manifested by escape from control mechanisms, increased 
growth potential, alterations in cell surface, karyotypic abnormalities, morphological 
and biochemical deviations, and other attributes conferring the ability to invade, 
metastasize and kill. 
Neoplastic transformation was associated with certain phenotypic changes in vitro, 
such as loss of contact inhibition (cells could grow over one another) and anchorage 
independence (cells formed colonies in soft agar). Anchorage independence could be 
described in the light of primary fibroblasts and many fibroblastic cell lines (e.g. 
BALB/c3T3, NIH-3T3, etc.) that had to attach to a solid surface before they could 
divide. They failed to grow when suspended in a viscous fluid or gel (e.g. agar or 
agarose). However when these cell lines were transformed, they were able to grow in 
a viscous fluid or gel and became anchorage-independent. The process, by which 
these phenotypic changes occurred, was assumed to be closely related to the 
process of in vivo carcinogenesis. Cells derived from transformed colonies after 
passaging in culture were capable of tumor formation when inoculated in a suitable 
host animal. 
Cell transformation soft agar assay was an anchorage-independent growth assay in 
soft agar, which was considered the most stringent assay for detecting malignant 
transformation of cells. For this assay, cells were cultured with appropriate control 
cells in soft agar medium for 21-28 days. Following this incubation period, formed 
colonies could be analyzed morphologically using cell stain solution. 
 
Material: 
Agarose powder 
Crystal violet (Sigma, Cat. No. C3886, USA) (Stock solution: 1% Crystal violet in 10% 
ethanol) 
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Cells: SCP1-40th P, SCP11-40th P, and SCP12-41st P.  Human fibrosarcoma cell 
line-HT1080 and non-transduced hMSCs-13th P were employed as positive and 
negative control. 
 
Methods: 
Ⅰ. Prepared 0.8% base agar layer as listed in below: 
 
Culture dish 96-well 48-well 24-well 6-well 35mm 60mm 100mm 
Volume(ml/well) 0.1 0.2 0.5 1.0 2.0 3.0 5.0 
 
Ⅱ. Prepared 0.4% top agar solution as listed in below: 
 
Culture dish 96-well 48-well 24-well 6-well 35mm 60mm 100mm 
Volume(ml/well) 0.05 0.1 0.25 0.5 1.0 1.5 2.5 
 
Ⅲ . Trypsinized and counted cells, harvested the appropriate number of cells 
according to table below by gentle centrifugation.  
 
Culture 
dish 
96-well 48-well 24-well 6-well 35mm 60mm 100mm 
Amount 
(cells/well) 
500 1000 1250 2500 5000 7500 12500 
Top agar 
with cells 
(ml/well) 
0.05 0.1 0.25 0.5 1.0 1.5 2.5 
 
Ⅳ. Resuspended harvested cells in appropriate amount of 0.4% top agar solution 
(37±2°C) according to the table above, made sure that a single cell suspension was 
obtained; aliquoted appropriately on top of base agar layer (pre-warmed to 37°C). A 
well containing only base and top agar layers without cells was included; this would 
serve as a background control.  
Ⅴ. Incubated cells for 28 days at 37oC with 5% CO2 until colonies were formed. 
Ⅵ. Fed cells 1-2 times per week with cell culture media. 
Ⅶ. Stained well plates with 0.005% crystal violet for 2 hour after 28 days of culture. 
Ⅷ. Took photograph under a microscope. 
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2.12.  In vivo implantation assay 
Material: 
Athymic nude mice (Harlan-Winkelmann, Borchen, Germany) 
HT1080 (ATCC, Cat. No.CCL-121, USA) 
 
Methods: 
Twenty athymic nude mice were divided into four groups with five mice in each group. 
A total of 1×106 cells of each cell type (SCP-1, SCP-11, untransduced hMSCs and 
HT1080) were suspended in 250 μl of phosphate buffered saline (PBS) and injected 
subcutaneously over the right ribcage. Injections were performed under general 
anaesthesia with isoflurane. Mice were sacrificed after 8 weeks by CO2 overdose. 
All procedures were performed according to German animal protection legislation and 
approved by the Government Committee of Upper Bavaria (file reference 07-07). 
Animals were kept in individually ventilated cages “type II long” (Tecniplast, Italy). 
Free access to food and water was secured at all times. 
 
Animals 
（number） 
Cells 
(1×106 /250 µl) 
Passage 
Sample harvesting 
time (number of 
animals) 
5 SCP 1 90 th 8 weeks (5) 
5 SCP 11 89 th 8 weeks (5) 
5 hMSCs 11 th 8 weeks (5) 
5 HT 1080  
10 days (4), 8 weeks 
(1) 
 
Photographs were taken for macroscopic evaluation. Skin and underlying soft tissue 
of the relevant area were dissected. Specimens were fixated in 4% paraformaldehyde. 
Samples were processed via cryosectioning. Samples were fixated and tissues were 
infiltrated with sucrose solution (3 hrs in 5% sucrose, 3 hrs in 10% sucrose, 12 hrs 
20% sucrose). Specimens were frozen in Tissue Freezing Medium (Jung, Germany). 
Serial cuts were prepared with a slice thickness of 12μm. Representative slides of 
each animal were stained with haematoxylin and eosin (H.E.) and investigated for 
possible tumour growth. 
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3.  Results 
3.1.  Construction of pLenti6/V5-hTERT and transduction of hMSCs 
hTERT was isolated from pBABE-PURO plasmid by digestion with Sal I and linearized 
with Klenow large fragment. pENTR11 plasmid was digested with NotI and blunt ends 
were generated by Klenow. The resulting pENTR11 vector and hTERT fragment were 
ligated using Quick T4 ligase and pENTR11-hTERT was constructed (Figure 5). The 
coding sequence of hTERT was then transferred from pENTR11 into pLenti6V5-Dest 
by using LR Clonase reaction (Figure 6). To confirm that hTERT was correctly 
transferred into pLenti6V5-Dest vector, expression construct of pLenti6V5-hTERT was 
sequenced. The sequencing result showed that the coding sequence in the 
expression construct was totally in accordance with the gene record from the 
database of “National Institute of Health (NIH)” (Supplement II) .   
 
 
Figure 5. Construct of pENTR11-hTERT.  hTERT was inserted into pENTR11 vector 
between the recombination sites attL1,2.  
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Figure 6. LR recombination reaction and construction of pLenti6/V5-hTERT. An LR 
recombination reaction was perfomed between the attL-containing entry clone 
pENTR11-hTERT and the attR-containing destination vector pLenti6/V5-DEST to generate an 
expression clone pLenti6/V5-hTERT. 
 
Lentivirous containing hTERT was generated by co-transfecting 293FT with 
pLenti6/V5-hTERT and packaging mix. hMSCs were transduced with 
pLenti6/V5-hTERT at 5th passage using 6 µg/ml Polybrene. Successfully transduced 
hMSCs were selected with 10 µg/ml Blasticidin for 10 days.  
 
3.2.  Expression of hTERT 
Ectopic hTERT overexpression was detected in lentiviral hTERT-transduced 
heterogenous hMSCs (TERT), clonal SCP1, SCP9, SCP11 and SCP12 around 10th 
passage (TERT-10P, SCP1-9P, SCP9-8P, SCP12-9P) (Figure.7A), and around 40th 
passage (SCP1-42P, SCP9-35P, SCP11-45P, SCP12-46P, TERT-44P) by RT-PCR, 
while not in non-transduced hMSCs (Figure.7B). 
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Figure. 7 RT-PCR of hTERT in hTERT-transduced hMSCs. hTERT mRNA was detected positive in 
hTERT-transduced heterogeneous hMSCs (showed as TERT), single-cell-picking clone 1 (SCP1), 
SCP9, SCP11, SCP12 around 10th passage (A. TERT-10P, SCP1-9P, SCP9-8P, SCP12-9P, 
hMSCs-11P) and around 40th passage (B. SCP1-42P, SCP9-35P, SCP11-45P, SCP12-46P, 
TERT-44P, hMSCs-5P); while no hTERT expression was detected in non-transduced hMSCs.  β-actin 
was amplified as control.  
 
3.3.  Growth kinetics of hTERT-transduced hMSCs cell lines 
Growth characteristics of clonal SCP1, SCP9, SCP11, SCP12, heterogeneous 
hMSCs-hTERT (TERT) and untranduced hMSCs were monitored by calculating 
cumulative population doubling level (PDL) and population doubling time (PDT). As 
showed in figure 8 and table 3, three distinct growth periods of hMSCs-hTERT could 
be noticed.  In the “initial period”, single cell picked clonal hMSCs-hTERT (SCP1, 
SCP9, SCP11 and SCP12) and heterogeneous hMSCs-hTERT had PDT from 2.3 to 
5.5 (PDL from 20.7 to 27.1), comparable to non-transduced hMSCs that it was 8.5 for 
PDT (21.0 for PDL). Then the growth of hMSCs-hTERT, either clonal or heterogenous, 
got into a growth “plateau period”, with PDT from 9.2 to 22.1 (PDL from 30.6 to 48.2), 
while non-transduced hMSCs got into senescence, with a negative PDT of -15.3.   
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After this growth-retarding plateau period, all of hMSCs-hTERT exhibited a higher 
growth rate, with PDT from 2.1 to 6.1 (PDL from 53.7 to 105.6), which was noticed as 
the “rapid-growing period”. Thus, both clonal single-cell-picking and heterogenous 
hTERT-transduced hMSCs experienced a similar growth pattern of three different 
periods: Initial, plateau and rapid-growing, showing that all hMSCs-hTERT bypassed 
senescence.  
 
 
 
Figure. 8 Cumulative population doubling level (PDL) of hMSCs-hTERT. Clonal SCP1, SCP9, SCP11, 
SCP12, heterogeneous TERT and non-transduced hMSCs. All hTERT-transduced hMSCs proliferated 
continuously. Three growth periods of SCP1 were showed being divided by two red vertical lines. 
Non-transduced hMSCs (blue dots) went into senescence. 
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Cell type Initial period Plateau period Rapid-growing period 
 PDL PDT PDL PDT PDL PDT 
SCP1 
27.1 
(1st  - 18th P) 
2.3 
48.2 
(19th - 49th P) 
10.9 
105.6 
(50th P~) 
2.1 
SCP9 
20.7 
(1st - 15th P) 
5.5 
30.6 
(16th - 49th P) 
22.1 
53.7 
(50th P~) 
3.9 
SCP11 
20.9 
(1st - 15th P) 
4.7 
38.2 
(16th - 52nd P) 
9.2 
82.9 
(53rd P~) 
3.7 
SCP12 
25.7 
(1st - 17th P) 
2.7 
46.5 
(18th - 66th P) 
20.6 
71.1 
(67th P~) 
6.1 
hTERT, 
heterogenous 
21.6 
(1st - 15th P) 
4.6 
48.1 
(16th - 68th P) 
12.2 
74.4 
(69th P~) 
3.8 
hMSCs 
21.0 
(1st - 18th P) 
8.5 
22.1 
(19th P~) 
-15.3 
Δ 
  
* PDL: cumulative population doubling level;    PDT: population doubling time in days. 
Δ Non-transduced hMSCs got into senescence.  
 
Table. 3 Cumulative population doubling level (PDL) and population doubling time (PDT) of 
hTERT-transduced hMSCs. hTERT-trancduced hMSCs experienced a three periods of growth, with 
PDT of 2.3-5.5 in the initial period, 9.2-22.1 in the plateau period and 2.1-6.1 in the rapid-growing 
period; while non-transduced hMSCs went into senescence with a negative PDT of -15.3.   
3.4.  Morphological change during passage 
In accordance to the growth characteristics, morphology of clonal and heterogenous 
hMSCs-hTERT changed with culture time.  In the initial period, most of clonal, 
heterogeneous hMSCs-hTERT and non-transduced hMSCs were small, round and 
spindle-shaped with less than 30% percent of flat cells (Figure. 9A). 90 days after 
single cell picking, hTERT-transduced cells grew slower with more cells changed their 
form into polygonal or flat (Figure. 9B), while almost all of the non-transduced hMSCs 
turned flat and broke into pieces (apoptosis). In the third part of growth period 
(rapid-growing), hTERT-transduced hMSCs regained and strengthened their 
proliferation capacity, while most of the cell became smaller and spindle-shaped and 
proliferated fast (Figure. 9C).    
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Figure. 9 Morphology change of hTERT-transduced hMSCs. 
Heterogenous hTERT-transduced hMSCs at 15th passage in the initial period (A), 42nd passage in the 
plateau period (B) and 74th passage in the rapid-growing period (C).  More flat cells were seen in the 
growth plateau period (B), while increased number of small, spindle-shaped cells were noticed in the 
third rapid-growing period (C).   
3.5.  Senescence associated β-gal staining 
Ectopic overexpression of hTERT in hMSCs extended the lifespan of the cells, thus 
bypassed replicative senescence. Senescence associated β-gal staining was a 
well-accepted staining method to discern senescent cells.  As shown in Figure 10, 
SCP1 of hTERT-transduced hMSCs had very low or undetectable 
senescence-associated β-gal staining at 42nd passage (Figure. 10A). In contrast, 
non-transduced hMSCs were strongly positive for β-galactosidase activity even at 24th 
passage, indicating that non-tranduced normal hMSCs would get into senescence 
even at earlier passage than hTERT-transduced hMSCs (Figure. 10B).  
 
 
 
C 
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Figure. 10 Senescence-associated β-gal staining of hTERT-transduced hMSCs. Clonal 
hTERT-transduced SCP1 was stained negative at 42nd passage (A), while non-transduced hMSCs 
were stained positive at 24th passage (B).  
A 
B 
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3.6.  Differentiation assay 
hMSCs-hTERT were induced into three mesodermal lineages (adipocytes, 
chondrocytes and osteoblasts) by lineage-specific inducing medium. All of the 
hTERT-transduced hMSCs maintained their differentiation capacity in response to 
inducing medium during long-term of culture. Intracellular lipid droplets were stained 
orange to red in adipogenic differentiation by Oil red O staining (Figure. 11A); 
extracullular proteoglycan was stained blue in chondrogenic differentiation (Figure. 
11C); deposited extracellular calcium was stained dark-black in osteogenic 
differentiation by van Kossa staining (Figure. 11E).  Lineage specific staining was 
low or negative in non-induced control (Figure. 11B,D,F).    
 
 
 
 
 
 
 
 
 
 
 
A 
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Figure 11. Differentiation assay of hTERT-transduced hMSCs. 
hMSCs-hTERT SCP1-47th passage were stained positive as orange-red in adipogenic 
differentiation(A), dark-blue in chondrogenic differentiation(C) and dark-black in osteogenic 
differentiation (E); while no or less staining was observed in non-induced control (B,D,F). 
3.7.  Karyotype （cytogenetics） analysis 
The hTERT-transduced hMSC clones SCP-1, SCP-11 and SCP-12 were found to be 
diploid with 46 chromosomes. There was no chromosomal aberration seen in SCP-1 
cell clones (Fig. 12A). In contrast, SCP-11 and SCP-12 showed an identical deletion 
of the long arm of chromosome 16 (Fig. 12B and C). In order to exclude a 
chromosomal aberration related to lentiviral gene transfer, we went back to the 
original untransduced hMSCs (passage 12) and young hTERT-transduced cells 
(passage 11 after transduction) from the same donor. Fluorescence in situ 
hybridization (FISH) revealed that these deletions have already been present in the 
donor cells before lentiviral transduction. In the sub-telomer analysis of untransduced 
hMSCs, 5 of 194 (2.6%) interphase nuclei contained only one signal for the region 
16qter (Fig. 12D and E). In heterogeneous hTERT-expressing hMSCs, 17 of 198 
(8.6%) interphase nuclei lacked one region of 16qter (Fig. 12F and G). These results 
F 
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indicate that the chromosomal aberration already existed in donor hMSCs before 
lentiviral transduction.  
 
 
 
Figure. 12 Karyotype (cytogenetics) analysis of hTERT-hMSCs. (A–C) Karyotyping revealed no 
change in hTERT-transduced SCP-1 clone (passage 92), while SCP-11 (passage 89) and SCP-12 
(passage 80) showed identical deletions in the long arm of chromosome 16 (16q). (D–G) FISH analysis 
revealed that these deletions already existed in younger passages of untransduced and 
hTERT-transduced hMSCs.  
3.8.  Tumor suppressor gene assay 
The expression level of tumor suppressor genes of RB1, TP53 and p21 were positive 
and comparable to non-transduced hMSCs by time-course RT-PCR detection at 
different passages, while TP53 was not detectable and p21 was down-regulated in 
osteosarcoma cell line-MG63 (Figure.13), suggesting that the growth of 
hTERT-transduced hMSCs was under control of these tumor suppressor genes, while 
it was not in MG63. 
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Figure. 13 Time course of expression of tumor suppressor genes---RB1, TP53 and p21 in different 
passages of hTERT-transduced hMSCs. The expression level of RB1, TP53 and p21 of clonal and 
heterogeneous hTERT-transduced hMSCs were positive and comparable to non-transduced hMSCs at 
different passages by time-course RT-PCR analysis; while TP53  was negative and p21 was 
down-regulated in osteosarcoma cell line—MG63.   
3.9.  Soft agar assay 
To check whether hMSCs-hTERT had got malignantly transformed, the anchorage 
independence capacity of these cells was checked in soft agar. SCP1-39P, SCP11- 
39P, SCP12-40P, hMSCs-13P failed to form colonies and remained as single cell in 
soft agar (Figure. 14A) after 28 days of culture, while fibrosarcoma HT1080 cells 
formed colonies in soft agar, showing the malignant characteristic of these 
transformed cells (Figure. 14B). 
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Figure. 14 Soft agar assay of TERT-transduced hMSCs. No colonies were formed in soft agar by 
hTERT-transduced SCP1-40P (A); while colonies were noticeably formed by H1080 in soft agar (B).   
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3.10.  In vivo implantation assay 
We tested whether hTERT-transduced hMSCs show tumour formation in vivo. 
Therefore, two clones (SCP-1 and -11), untransduced hMSCs and the tumour cell line 
HT1080 were injected subcutaneously into five nude mice each. None of the animals 
in the SCP-1, SCP-11 and hMSC groups developed a macroscopically detectable 
tumour by 8 weeks after implantation (Fig. 15A). Four of five animals in the HT1080 
group were sacrificed 10 days after injection because of extensive tumour growth at 
the site of injection (Fig. 15C). The fifth animal had a macroscopically visible tumour 
upon explantation after 8 weeks. Histological evaluation of the injection sites 
confirmed the macroscopic findings. In all the animals from the SCP-1, SCP-11 and 
hMSC groups, a normal structure of the skin and subcutaneous tissue was observed 
(Fig. 15B). At the same time, extensive tumour growth was observed at the site of 
injection of all the animals that had received HT1080 cells (Fig. 15D). 
 
 
 
Figure 15. In vivo tumor formation assay. HTERT-transduced hMSCs (here shown SCP-1) did not 
show macroscopic (A) and microscopic (B, HE stain) after 8 weeks. In contrast, HT1080 formed 
macroscopically visible tumors within 1 week (C). H.E. stain revealed a characteristic tumor growth (D). 
A B 
C D 
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4.  Discussion 
4.1.  Senescence of hMSCs hindered its usge as tissue engineering 
seed cell 
Although hMSCs has a remarkable self-renewing capacity, no telomerase activity was 
detectable in hMSCs strains established from different donors (Kolquist et al. 1998). 
Telomere length of expanded hMSCs was also not longer than that of expanded 
somatic chondrocytes (Parsch et al. 2004). With continuous passaging of hMSCs in 
vitro, as a result of continuous telomere shortening and DNA damage caused by 
reactive oxygen species (ROS) and other cytotoxic agents, primary hMSCs would get 
into aging (senescence) or apoptosis, as shown in Figure 8.  As for tissue 
engineering, a big amount of seed cells were needed for constructing 
tissue-engineered tissue or organ in vitro. But being limited by low incidence of MSC 
in human bone or adipose tissue(1/105~1/104), researchers always needed to expand 
and passage isolated hMSCs for a relative long time in vitro, thus predisposed hMSCs 
to pre-senescence[3], hindering its usage in tissue engineering. 
4.2.  Transduction with telomerase reverse transcriptase (hTERT) 
would bypass senescence  
Telomerase reverse transcriptase (TERT), the catalytic unit of telomerase, was the 
key deciding factor that maintained and prolonged telomere length. In this way, 
telomerase could rescue cell from telomere length-dependent proliferation check, 
prevented uncapping of chromosome ends and resultant chromosome fusion, thus 
stabilized the chromosome and extended life span of cells.  Successful transduction 
of human TERT (hTERT) and lengthening of lifespan (immortalization) were reported 
in different human cell types. Among them, B.M. Abdallah et al had passaged hMSCs 
for more than 3 years with cumulative population doubling level (PDL) of more than 
430 by using retroviral vector to transduce hTERT into cells (Abdallah et al. 2005).  In 
our experiment, lentiviral vector was employed to transduce hMSCs with hTERT 
(Figure.6). As shown in Figure 7, all of the hTERT transduced hMSCs, 
single-cell-picking clone and heterogeneous cells, overexpressed hTERT; while 
non-transduced hMSCs had no detectable hTERT expression at all. 
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hTERT-transduced hMSCs proliferated continuously, reaching more than 200 PDL for 
nearly 530 days (single-cell-picking clone 1-SCP1), while non-transduced hMSCs got 
into replicative senescence, with the cells were reduced in harvested cell number and 
a negative population doubling (Figure 8, Table 3). At the same time, hMSCs-hTERT 
were stained negative for well-accepted senescence-associated β-gal staining (Figure 
10A), while non-transduced hMSCs stained positive (Figure 10B) indicating that these 
cells were senescent (Xu et al. 2004;Dimri et al. 1995). Thus, the data from our 
experiment proved that lentiviral hTERT-transduction could expand the life-span 
(immortalize) of hMSCs, bypass the replicative senescence.  
 
There was also a trend to be noticed in the proliferation of hTERT-transduced hMSCs. 
As showed in Figure 8 and Table 3, proliferation of hMSCs-hTERT could be divided 
into three parts: initial period, plateau period and rapid-growing period.  In the “initial 
period”, hTERT-transduced hMSCs had population doubling time from 2.3 days to 5.5 
days. After that, the proliferation rate of hTERT-transduced hMSCs became slower 
and the cells got into a “growth plateau’, with a prolonged PDT from 9.2 days to 22.1 
days. Closely accompanying this phenomenon, non-transduced hMSCs went into 
replicative senescence, with dramatic reduction in cell number and negative PDT.  
While in the “rapid-growing period”, all of the hTERT-transduced hMSCs seemed to 
regain their proliferation capacity, with a shortened PDT from 2.1 days to 6.1 days.   
Similar to changes in the growth pattern, morphological changes were also observed 
in this three periods. More cells changed from small, spindle-shaped into polygonal or 
flat when the cells grew from “initial period” into “plateau period”, and when cells 
regained and strengthened their proliferation capacity in “rapid-growing period”, most 
of them regressed smaller and spindle-shaped (Figure 9). These results were quite in 
accordance with the observation of D.C. Colter et al. In their researches, 
morphologically smaller type I hMSCs (rapid self-renewing cells) had more rapid rate 
of replication and enhanced potential for multilineage differentiation than inactive flat 
type II cells (Mets and Verdonk 1981;Colter et al. 2001).  
 
As the growth “plateau period” began quite in time with the beginning of growth 
declination (senescence) of non-transduced hMSCs in our experiment, a possible 
explanation for the growth “plateau period” could be that, due to accumulative 
damage to DNA and organelles induced by reactive oxygen species (ROS) and other 
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toxic reagent in continuous ex vivo culture, heterogeneous hMSCs-hTERT, and also 
the cells in single-cell-picking clone that had different metabolic status being 
influenced by in vitro culture circumstances, experienced a “self-selection” process. 
Morphologically bigger, flat type II cells in the cell-pool of hMSCs-hTERT with lower 
self-renewing capacity went into senescence or apoptosis, while the cells with intact 
chromosome and higher self-renewing capacity survived, thus contributing to the 
prominent growth capacity in the third rapid-growing period. Yet, the mechanism 
behind this reflection needed to be further investigated.  
4.3.  Differentiation capability was not hampered by hTRET 
transduction and long term in vitro culture 
Long-term in vitro culture of hMSCs usually resulted in impaired differentiation 
capacity, thus limited the feasibility of expanding hMSCs to a large number of cells 
that was needed for therapeutic applications.  During in vitro subculturing, human 
osteoblasts showed impaired osteogenic potential evidenced by decreased 
expression of osteoblast-specific genes, such as core-binding factor 1/Runt-related 
transcription factor 2 (Cfba1/Runx2), alkaline phosphatise (ALP), collagen type I (Col I) 
and osteocalcin (OC) (Christiansen et al. 2000). Marrow stromal cells failed to 
differentiate into adipocytes following serial passage in continuous culture (Digirolamo 
et al. 1999).  As the loss of differentiation capacity was related to aging (senescence) 
of the cells, researchers transduced hMSCs with hTERT and proved that ectopic 
hTERT expression by retroviral vector could maintain differentiation potential and 
even enhance osteogenesis of hMSCs (Shi et al. 2002;Simonsen et al. 2002).   
 
In our experiment, differentiation potential of lentivirally hTERT-transduced hMSCs 
were checked at different passages (47, 52, 68, 80, 82 passages), all of the clonal and 
heterogeneous hMSCs-hTERT were capable of differentiating into osteogenic (von 
Kossa stain positive), adipogenic (Oil red O stain positive) and chondrogenic 
(Toluidine blue stain positive) lineage (Figure 11).  These results confirmed the 
notion that ectopic expression of hTERT in hMSCs by lentiviral vector would extend 
the proliferative life-span (immortalize) of hMSCs and would not interfere with the 
differentiation potential of hMSCs, thus providing a practical method to construct a 
hMSCs cell line both for in vitro experiment on the biology of hMSCs and also for 
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therapeutic application of hMSCs in vivo.  Additionally, single cell picking could offer 
a convenient way to establish genetically identical hMSCs-hTERT clone that had the 
same genetic background for further characterization of hMSCs.  
4.4.  Replication incompetent HIV-1-based lentiviral vector 
transduction weighed better than traditional Moloney Leukemia 
Virus (MoMLV)-based retroviral transduction       
Viral transduction of gene of interest (GOI) into target cell was an efficient way to 
express target gene. Till now, all of the authors employed MoMLV-based retroviral 
vector to transduce hMSCs with hTERT and gained positive results. Nevertheless, 
due to its specific transduction feature, transduction of GOI with retroviral vectors had 
disadvantages in application. First, MoMLV-based retroviral vectors could only infect 
dividing cells. Second, MoMLV-based retroviral vectors had a bias of integration site 
selection. Based on tumor-prone cyclin-dependent kinase inhibitor 2a (Cdkn2a) –/– 
mouse model, E. Montini et al exploited hematopoietic stem cells to compare the 
oncogenicity of prototypical retroviral and lentiviral vectors. They transduced 
hematopoietic stem cells in matched clinically relevant conditions, and compared 
integration site selection and tumor development in transplanted mice. After 450 days 
of observation, they noticed that retroviral vectors triggered dose-dependent 
acceleration of tumor onset contingent on long terminal repeat (LTR) activity. In 
contrast, tumorigenesis was unaffected by lentiviral vectors and did not enrich for 
specific integrants, despite the higher integration load and robust expression of 
lentiviral vectors in all hematopoietic lineages. They found out that retroviral vector 
integrations had an additional hot spot upstream of the transcriptional start site (TSS) 
of genes. This pattern might increase the potential for strong enhancer elements in 
the retroviral LTR to transactivate the adjacent cellular gene promoter. They also 
showed that a statistically significant bias of retroviral vectors for cancer-associated 
genes (as defined in retrovirus tagged cancer gene database-RTCGD), gene ontology 
(GO) classes such as transcription factors, and genes associated with cell cycle 
control, which underlay the mechanism of insertional oncogenesis (Kohn 2007;Akagi 
et al. 2004;Montini et al. 2006).  So due to their intrinsic infection spectrum and 
integration feature, MoMLV-based retroviral vector had disadvantages in hTERT gene 
transduction into hMSCs. 
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Another factor that might be involved in the malignant transformation of retroviral 
hTERT-transduction experiment was the long term in vitro culture. Researchers had 
observed that, after numerous in vitro passages, murine bone marrow-derived MSC 
had acquired spontaneous accumulated chromosomal abnormalities and malignant 
transformation. They also noticed that this transformation was associated with 
increased c-myc expression [14].  As telomerase activity and hTERT expression 
were normally maintained in germline cells, embryonic stem cells and some active 
somatic cells and these cells were not malignantly transformed [11]. Based on these 
observations, one speculation could be prompted that, that were the specific trait of 
MoMLV-based retroviral vectors used in hTERT transduction, accumulated 
chromosomal instability and growth selection during long-term in vitro culture that 
predisposed hTERT-transduced hMSCs to neoplastic transformation.  
 
Replication incompetent HIV-1-based lentiviral vector was employed in our 
experiment to transduce hMSCs with hTERT. This lentiviral vector could transduce 
both dividing and non-dividing mammalian cells, thus having a broadened spectrum of 
application beyond traditional MoMLV-based retroviral vectors. It also had a different 
integration-site selection pattern, targeting gene-rich regions at even higher frequency 
and integration loads than retroviruses but without the predilection for the 5’ ends 
(TSS) of genes and even lower genotoxic effects (Biffi et al. 2004;Hematti et al. 
2004;De Palma et al. 2005). Lentiviral vector in our experiment was developed by 
using design strategies to optimize safety and effectiveness, such as ‘self-inactivation’ 
by a deletion in the 3’ LTR, minimal viral sequences in the transfer vector, splitting 
genes for packaging functions over multiple plasmids and pseudotyping with 
alternative VSV-G envelope proteins. In these ways, replication incompetent 
HIV-1-based lentiviral vector transduction of gene of interest weighed better than 
traditional MoMLV-based retroviral transduction.  
4.5.  No malignant transformation was observed in lentiviraly 
hTERT- transduced hMSCs 
The persistence and continued mitotic activity of stem cells throughout life made 
these cells a potential reservoir for the accumulation of oncogenic mutations. The 
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self-renewal mechanisms that allowed stem cells to persist consistently involve 
proto-oncogene pathways such as Wnt, Shh and Notch. The activation of these 
pathways in stem cells throughout life might predispose these cells to neoplastic 
transformation. There were evidences that some cancers arose from mutations that 
transformed stem cells (Kiyokawa 2006;Reya et al. 2001).  
 
The danger of neoplastic transformation being originated from constitutively activated 
self-renewal pathways in stem cells made it critical to incorporate tumor suppressor 
mechanisms into this process. Tumor suppressors came in two varieties: ’’caretakers’’, 
such as ataxia telangiectasia mutated (ATM), that prevented mutations by detecting 
and promoting the repair of DNA damage, and ‘’gatekeepers’’ that promoted 
senescence or cell death when cells became mutated or stressed. Predominantly, 
cells growth and DNA replication were under surveillance of two well-established 
pathways, RB1 and TP53 that acted as “gatekeepers” to promote senescence or cell 
death when cells became mutated or stressed (Pardal et al. 2005) (Figure 16).  
 
 
 
Figure.16 The RB1 and TP53 pathways in tumor suppression and cell cycle control. (p16 INK4a: 
cyclin-dependent kinase inhibitor 2A; p14ARF: alternative reading frame (of INK4a/ARF locus) 
TP53 
RB1 
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CDK2/4/6: cyclin-dependent kinase 2/4/6; RB1: retinoblastoma 1; E2F: E2F transcription factors; 
MDM2: mouse double minute 2 homolog; TP53: tumor protein 53; p21: cyclin-dependent kinase 
inhibitor 1A) 
 
As showed in Figure 16, in the unstressed state, TP53 was rapid degraded by MDM2; 
a process which was inhibited by ARF. Also, TP53 could be stalilized by N-terminal 
serine phosphorylation in response to genotoxic stresses such as DNA damage, 
oncogene activation and cellular stresses, and this phosphorylation inhibited its 
interaction with MDM2. TP53 activation potently induced either senescence or 
apoptosis. The “gatekeeping” activity of TP53 in part resulted from p21 expression, 
which was a TP53 transcriptional target. RB1 pathway also took an important effect in 
cell cycle control, which crossed out mutated cells by growth arrest induction 
(Sharpless and DePinho 2004).   
 
As the RB1 and TP53 pathways were very important in balancing the effect of letiviral 
hTERT-transduction and accumulative chromosomal stability, it was very necessary 
to detect these genes in the hTERT-transduced hMSCs in different culture period. 
Time-course analysis of RB1 and TP53 expression were showed in Figure 13, in three 
different proliferation periods, these two key tumor suppressors were not 
down-regulated, suggesting the growth of hTERT-transduced hMSCs were under 
control of these “gatekeeping” tumor suppressing genes.  This result was consistent 
with the result of other authors (Chapman et al. 2006;Terai et al. 2005). In order to 
check the potential malignant transformation of our lentiviral hTERT-transduced cells 
further, anchorage independence soft agar assay and nude mice implantation assay 
were employed. When being checked with in vitro soft agar colony-forming assay and 
in vivo implantation tumor-forming assay, our lentiviral hTERT-transduced hMSCs did 
not form any colonies in vitro (Figure. 14) or any tumors in vivo (Figure 15). 
 
Transformation of retrovirally hTERT-transduced cells reported in other researches 
[12] might have evolved from spontaneous chromosomal aberrations in prolonged 
culture with multiple cell divisions and might not have been directly related to ectopic 
hTERT expression. This hypothesis was supported by the finding that spontaneous 
accumulation of chromosomal abnormalities and malignant transformation occurred 
after numerous passages even in untransduced murine bone marrow-derived MSCs 
[14]. On the other hand, mathematical modelling indicated that rather a selective 
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growth of cells with mutations in tumour suppressor genes was the driving force in the 
development of most human tumours, than an increased mutation rate. Spontaneous 
transformation in cultured cells was efficiently evoked by progressive selection under 
prolonged contact inhibition at high population density or during multiplication at low 
population density in suboptimal concentrations or types of serum (Rubin 2001). 
Therefore, malignant transformation of hTERT-transduced hMSCs might have been 
the result of progressive selection of malignant cells under particular culture 
conditions. Since germline cells, embryonic stem cells and some active somatic cells 
expressed hTERT in vivo and many different cell types had been immortalized by 
hTERT without malignant transformation, hTERT was not considered an oncogene 
[11] and cells transduced by hTERT was not destined to be malignantly transformed. 
In our experiment, karyotype (cytogenetics) analysis was employed to check 
chromosomal status of hTERT transduced hMSC, subtelomeric chromosomal 
deletion of 16q was found in SCP11 and SCP12 while it was normal in SCP1; 
retrospective FISH analysis revealed that this deletion already existed in donor 
hMSCs (2.6%) before lentiviral transduction. With prolonged growth time in vitro 
supported by hTERT transduction, the deletion on chromosome 16 might be 
accumulated with culture time. The lentivirally hTERT-transduced hMSCs clones in 
our experiment were proved to be not transformed by karyotpe, soft agar, tumor 
supressor gene and in vivo implatation assays, nevertheless a dose-dependant 
tumour acceleration triggered by retroviral vectors employed in other experiments 
reminded us that caution would be taken in the use of lentivirally hTERT-immortalized 
hMSCs in cell and gene therapy applications, and monitoring of genetic instability and 
accumulation of mutations of these cells would also be needed.  
 
In summary, we reported for the first time a hMSC clone successfully immortalized by 
ectopic expression of hTERT using lentiviral gene transfer. The immortalized clonal 
hMSCs revealed no change of karyotype with no signs of malignant transformation in 
vitro and in vivo, making them an attractive candidate for cell and gene therapy 
applications. Nevertheless, due to a potential risk of selecting preexisting tumour cells, 
careful screening for mutations and malignant transformation was mandatory.  
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5.  Summary 
Objective: 
To establish a immortalized hMSCs cell line by hTERT transduction using lentiviral 
vector; 
To explore the biological effect of lentiviral hTERT transduction on hMSCs; 
To elucidate the transformation potential of hTERT-transduction in hMSCs. 
 
Material and Methods: 
hMSCs were infected with lentivirus containing hTERT, clonal hMSCs-hTERT was 
obtained by single cell picking. Expression of hTERT was confirmed by RT-PCR in 
hMSCs-hTERT. Cell proliferation was monitored by morphological observation and 
population doubling level (PDL) and population doubling time (PDT) calculation. 
Senescence-bypassing effect of hTERT-transduction was confirmed by 
senescence-associated β -gal staining with non-transduced hMSCs as control. 
Differentiation capacity of hMSCs-hTERT was checked by adipogenic, chondrogenic 
and osteogenic induction. In order to elucidate the potential transformation capacity of 
lentiviral hTERT-tranduction in hMSCs, karyotype and FISH analysis, time course 
tumor suppressor genes assay of RB1, TP53 and p21, in vitro soft agar assay and in 
vivo nude mice implantation assay were employed to check both the clonal and 
heterogeneous hMSCs-hTERT. 
 
Results: 
hTERT was successfully tranduced into hMSCs and single-cell-picking clones (SCP) 
were established. hTERT expression was confirmed in hTERT-tranduced hMSCs by 
RT-PCR but not detected in non-transduced hMSCs. Both clonal and heterogeneous 
hTERT-transduced hMSCs had grown for more than 500 days and proliferated still 
continuously, while non-transduced had gotten into senescence for less than 250 
days. A three periods of proliferation of hMSCs-hTERT could be noticed with different 
proliferation capacity and different PDT, PDL.  Cell morphology of hMSCs-hTERT 
changed from mixed phenotype in “initial period” (PDT 2.3 to 5.5, PDL 20.7 to 27.1) to 
high incidence of flat cell in “plateau period” (PDT 9.2 to 22.1, PDL 30.6 to 48.2)  
which was quite in accordance with the senescence process of non-transduced 
hMSCs, and then to high incidence of small, spindle-shaped cells (PDT 2.1 to 6.1, 
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PDL 53.7 to 105.6) in “rapid-growing period”, indicating the potential “self-selection” 
process in continuous in vitro culture. The differentiation capacity of 
hTERT-transduced hMSCs was confirmed both in clonal and heterogeneous 
hMSCs-hTERT by positive adipogenesis-specific Oil red O staining, 
chondrogenesis-specific toluidine blue staining and osteogenesis-specific von Kossa 
staining. Malignant transformation of hMSCs-hTERT was excluded by karyotype 
analysis, persistent tumor suppressor genes expression (RB1, TP53 and p21), no 
colonies formation in soft agar in vitro and no tumor formation in nude mice in vivo. 
 
Conclusion: 
In summary, we firstly reported that lentiviral transduction of hTERT was an efficient 
and relative secure way to generate an “immortalized” (life-span extended) hMSCs 
cell line. Although it needed to be checked for differentiation capacity and 
tumorigenetic potential for considerable even longer time, but based on our more than 
500 days of in vitro culture, clonal lentiviral hTERT-transduced hMSCs were proved to 
be a promising cell line to be applied in researches on the biological behaviour of 
hMSCs, and also for therapeutic applications in tissue engineering.  
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Supplement 
I. Protocol  
Producing Lentivirus in 293FT Cells in T-225 flask 
Materials 
• Lentiviral packaging mix (Invitrogen) 
• pLenti expression vector containing your gene of interest (endotoxin free) 
• 293FT cells cultured in complete growth medium containg 500µg/ml Geneticin 
(You will need 8 x 106 293FT cells for each sample) 
• Lipofectamine™ 2000 transfection reagent (store at +4°C and mix gently before 
use; DO not vortex; Never freeze) 
• Opti-MEM® I Reduced Serum Medium (pre-warmed; see the next page) 
• Fetal bovine serum (FBS) 
• Complete growth medium (i.e. D-MEM containing 10% FBS, 2 mM L-glutamine, 
0.1 mM MEM Non-Essential Amino Acids, 1% penicillin-streptomycin, and 1 mM MEM 
Sodium Pyruvate) 
• Sterile, T-75 tissue culture flasks (one for each lentiviral construct) 
• 5 ml sterile polystyrol tubes 
• Sterile, tissue culture supplies 
• 50 ml sterile, capped, conical tubes 
• 15 ml sterile, capped, conical tubes 
 
Transfection Procedure 
1. For each transfection sample, prepare DNA-Lipofectamine™ 2000 complexes 
as follows: 
a. In a sterile 5 ml polystyrol tube, dilute:  
11,9 µg (11,9 µl) ViraPower lentiviral packaging mix, and  
3,97 µg of pLenti expression plasmid DNA  
-pLenti-RFP (0,661 µg/µl): 6,0 µl 
-pLenti-GFP (0,2 µg/µl): 19,9 µl 
-pLenti-BFP (1 µg/µl): 4,0 µl 
-pLenti-Tet-ON-dBla (0,98 µg/µl): 4,1 µl 
in 1.98 ml of Opti-MEM® I Medium without serum. Mix gently. 
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b. In a separate sterile 5 ml polystyrol tube, mix Lipofectamine™ 2000 gently before 
use, then dilute 47,6µl in 1,98 ml of Opti-MEM® I Medium without serum. Mix gently 
and incubate for 5 minutes at room temperature. 
c. After the 5 minute incubation, combine the diluted DNA with the diluted 
Lipofectamine™ 2000. Mix gently. 
d. Incubate for 20 minutes at room temperature to allow the DNA-Lipofectamine™ 
2000 complexes to form. 
2. Trypsinize and count the 293FT cells. Resuspend the cells at a density of 1,2 x 106 
cells/ml in Opti-MEM® I Medium containing 10% fetal bovine serum. Do not include 
antibiotics in the medium. 
3. Add the DNA-Lipofectamine™ 2000 complexes to a T-75 tissue culture flask 
containing 6,61 ml Opti-MEM® I Medium containing serum. Do not include 
antibiotics in the medium. 
4. Add 6,61 ml of the 293FT cell suspension (7,9 x 106 total cells) to the flask 
containing media and DNA-Lipofectamine™ 2000 complexes. Mix gently by rocking 
the flask back and forth. Incubate cells for 6 h at 37°C in a CO2 incubator. 
5. After 6 h incubation, remove the medium containing the DNA-Lipofectamine™ 
2000 complexes and replace with 10 ml complete culture medium. 
6. Harvest virus-containing supernatants 45 hours posttransfection by removing 
medium to a 15 ml sterile, capped, conical tube. 
7. Centrifuge at 3000 rpm for 15 minutes at 4°C to pellet cell debris. Collect viral 
supernatant. 
8. Store viral stocks in aliquots at -80°C. 
       
 
 
 
 
 
 
 
 
 
 
Anhang   74 
II. Sequencing result of pLenti6/V5-hTERT 
 
    1  ttaagtttga ccttaggtca ctggaaagat gtcgagcgga tcgctcacaa 
       aattcaaact ggaatccagt gacctttcta cagctcgcct agcgagtgtt 
 
   51  ccagtcggta gatgtcaaga agagacgttg ggttaccttc tgctctgcag 
       ggtcagccat ctacagttct tctctgcaac ccaatggaag acgagacgtc 
 
  101  aatggccaac ctttaacgtc ggatggccgc gagacggcac ctttaaccga 
       ttaccggttg gaaattgcag cctaccggcg ctctgccgtg gaaattggct 
 
  151  gacctcatca cccaggttaa gatcaaggtc ttttcacctg gcccgcatgg 
       ctggagtagt gggtccaatt ctagttccag aaaagtggac cgggcgtacc 
 
  201  acacccagac caggtcccct acatcgtgac ctgggaagcc ttggcttttg 
       tgtgggtctg gtccagggga tgtagcactg gacccttcgg aaccgaaaac 
 
  251  acccccctcc ctgggtcaag ccctttgtac accctaagcc tccgcctcct 
       tggggggagg gacccagttc gggaaacatg tgggattcgg aggcggagga 
 
  301  cttcctccat ccgccccgtc tctccccctt gaacctcctc gttcgacccc 
       gaaggaggta ggcggggcag agagggggaa cttggaggag caagctgggg 
 
  351  gcctcgatcc tccctttatc cagccctcac tccttctcta ggcgccggcc 
       cggagctagg agggaaatag gtcgggagtg aggaagagat ccgcggccgg 
 
  401  ggatcccagt gtggtggtac gtaggaattc gtcctgctgc gcacgtggga 
       cctagggtca caccaccatg catccttaag caggacgacg cgtgcaccct 
 
  451  agccctggcc ccggccaccc ccgcgatgcc gcgcgctccc cgctgccgag 
       tcgggaccgg ggccggtggg ggcgctacgg cgcgcgaggg gcgacggctc 
                                  >>.........hTERT..........> 
                                    m   p  r  a  p   r  c  r 
 
  501  ccgtgcgctc cctgctgcgc agccactacc gcgaggtgct gccgctggcc 
       ggcacgcgag ggacgacgcg tcggtgatgg cgctccacga cggcgaccgg 
       >.......................hTERT........................> 
        a  v  r   s  l  l  r   s  h  y   r  e  v   l  p  l  a 
 
  551  acgttcgtgc ggcgcctggg gccccagggc tggcggctgg tgcagcgcgg 
       tgcaagcacg ccgcggaccc cggggtcccg accgccgacc acgtcgcgcc 
       >.......................hTERT........................> 
         t  f  v   r  r  l   g  p  q  g   w  r  l   v  q  r 
 
  601  ggacccggcg gctttccgcg cgctggtggc ccagtgcctg gtgtgcgtgc 
       cctgggccgc cgaaaggcgc gcgaccaccg ggtcacggac cacacgcacg 
       >.......................hTERT........................> 
       g  d  p  a   a  f  r   a  l  v   a  q  c  l   v  c  v 
 
  651  cctgggacgc acggccgccc cccgccgccc cctccttccg ccaggtgtcc 
       ggaccctgcg tgccggcggg gggcggcggg ggaggaaggc ggtccacagg 
       >.......................hTERT........................> 
        p  w  d   a  r  p  p   p  a  a   p  s  f   r  q  v  s 
 
  701  tgcctgaagg agctggtggc ccgagtgctg cagaggctgt gcgagcgcgg 
       acggacttcc tcgaccaccg ggctcacgac gtctccgaca cgctcgcgcc 
       >.......................hTERT........................> 
         c  l  k   e  l  v   a  r  v  l   q  r  l   c  e  r 
 
  751  cgcgaagaac gtgctggcct tcggcttcgc gctgctggac ggggcccgcg 
       gcgcttcttg cacgaccgga agccgaagcg cgacgacctg ccccgggcgc 
       >.......................hTERT........................> 
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       g  a  k  n   v  l  a   f  g  f   a  l  l  d   g  a  r 
 
  801  ggggcccccc cgaggccttc accaccagcg tgcgcagcta cctgcccaac 
       ccccgggggg gctccggaag tggtggtcgc acgcgtcgat ggacgggttg 
       >.......................hTERT........................> 
        g  g  p   p  e  a  f   t  t  s   v  r  s   y  l  p  n 
 
  851  acggtgaccg acgcactgcg ggggagcggg gcgtgggggc tgctgctgcg 
       tgccactggc tgcgtgacgc cccctcgccc cgcacccccg acgacgacgc 
       >.......................hTERT........................> 
         t  v  t   d  a  l   r  g  s  g   a  w  g   l  l  l 
 
  901  ccgcgtgggc gacgacgtgc tggttcacct gctggcacgc tgcgcgctct 
       ggcgcacccg ctgctgcacg accaagtgga cgaccgtgcg acgcgcgaga 
       >.......................hTERT........................> 
       r  r  v  g   d  d  v   l  v  h   l  l  a  r   c  a  l 
 
  951  ttgtgctggt ggctcccagc tgcgcctacc aggtgtgcgg gccgccgctg 
       aacacgacca ccgagggtcg acgcggatgg tccacacgcc cggcggcgac 
       >.......................hTERT........................> 
        f  v  l   v  a  p  s   c  a  y   q  v  c   g  p  p  l 
 
 1001  taccagctcg gcgctgccac tcaggcccgg cccccgccac acgctagtgg 
       atggtcgagc cgcgacggtg agtccgggcc gggggcggtg tgcgatcacc 
       >.......................hTERT........................> 
         y  q  l   g  a  a   t  q  a  r   p  p  p   h  a  s 
 
 1051  accccgaagg cgtctgggat gcgaacgggc ctggaaccat agcgtcaggg 
       tggggcttcc gcagacccta cgcttgcccg gaccttggta tcgcagtccc 
       >.......................hTERT........................> 
       g  p  r  r   r  l  g   c  e  r   a  w  n  h   s  v  r 
 
 1101  aggccggggt ccccctgggc ctgccagccc cgggtgcgag gaggcgcggg 
       tccggcccca gggggacccg gacggtcggg gcccacgctc ctccgcgccc 
       >.......................hTERT........................> 
        e  a  g   v  p  l  g   l  p  a   p  g  a   r  r  r  g 
 
 1151  ggcagtgcca gccgaagtct gccgttgccc aagaggccca ggcgtggcgc 
       ccgtcacggt cggcttcaga cggcaacggg ttctccgggt ccgcaccgcg 
       >.......................hTERT........................> 
         g  s  a   s  r  s   l  p  l  p   k  r  p   r  r  g 
 
 1201  tgcccctgag ccggagcgga cgcccgttgg gcaggggtcc tgggcccacc 
       acggggactc ggcctcgcct gcgggcaacc cgtccccagg acccgggtgg 
       >.......................hTERT........................> 
       a  a  p  e   p  e  r   t  p  v   g  q  g  s   w  a  h 
 
 1251  cgggcaggac gcgtggaccg agtgaccgtg gtttctgtgt ggtgtcacct 
       gcccgtcctg cgcacctggc tcactggcac caaagacaca ccacagtgga 
       >.......................hTERT........................> 
        p  g  r   t  r  g  p   s  d  r   g  f  c   v  v  s  p 
 
 1301  gccagacccg ccgaagaagc cacctctttg gagggtgcgc tctctggcac 
       cggtctgggc ggcttcttcg gtggagaaac ctcccacgcg agagaccgtg 
       >.......................hTERT........................> 
         a  r  p   a  e  e   a  t  s  l   e  g  a   l  s  g 
 
 1351  gcgccactcc cacccatccg tgggccgcca gcaccacgcg ggccccccat 
       cgcggtgagg gtgggtaggc acccggcggt cgtggtgcgc ccggggggta 
       >.......................hTERT........................> 
       t  r  h  s   h  p  s   v  g  r   q  h  h  a   g  p  p 
 
 1401  ccacatcgcg gccaccacgt ccctgggaca cgccttgtcc cccggtgtac 
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       ggtgtagcgc cggtggtgca gggaccctgt gcggaacagg gggccacatg 
       >.......................hTERT........................> 
        s  t  s   r  p  p  r   p  w  d   t  p  c   p  p  v  y 
 
 1451  gccgagacca agcacttcct ctactcctca ggcgacaagg agcagctgcg 
       cggctctggt tcgtgaagga gatgaggagt ccgctgttcc tcgtcgacgc 
       >.......................hTERT........................> 
         a  e  t   k  h  f   l  y  s  s   g  d  k   e  q  l 
 
 1501  gccctccttc ctactcagct ctctgaggcc cagcctgact ggcgctcgga 
       cgggaggaag gatgagtcga gagactccgg gtcggactga ccgcgagcct 
       >.......................hTERT........................> 
       r  p  s  f   l  l  s   s  l  r   p  s  l  t   g  a  r 
 
 1551  ggctcgtgga gaccatcttt ctgggttcca ggccctggat gccagggact 
       ccgagcacct ctggtagaaa gacccaaggt ccgggaccta cggtccctga 
       >.......................hTERT........................> 
        r  l  v   e  t  i  f   l  g  s   r  p  w   m  p  g  t 
 
 1601  ccccgcaggt tgccccgcct gccccagcgc tactggcaaa tgcggcccct 
       ggggcgtcca acggggcgga cggggtcgcg atgaccgttt acgccgggga 
       >.......................hTERT........................> 
         p  r  r   l  p  r   l  p  q  r   y  w  q   m  r  p 
 
 1651  gtttctggag ctgcttggga accacgcgca gtgcccctac ggggtgctcc 
       caaagacctc gacgaaccct tggtgcgcgt cacggggatg ccccacgagg 
       >.......................hTERT........................> 
       l  f  l  e   l  l  g   n  h  a   q  c  p  y   g  v  l 
 
 1701  tcaagacgca ctgcccgctg cgagctgcgg tcaccccagc agccggtgtc 
       agttctgcgt gacgggcgac gctcgacgcc agtggggtcg tcggccacag 
       >.......................hTERT........................> 
        l  k  t   h  c  p  l   r  a  a   v  t  p   a  a  g  v 
 
 1751  tgtgcccggg agaagcccca gggctctgtg gcggcccccg aggaggagga 
       acacgggccc tcttcggggt cccgagacac cgccgggggc tcctcctcct 
       >.......................hTERT........................> 
         c  a  r   e  k  p   q  g  s  v   a  a  p   e  e  e 
 
 1801  cacagacccc cgtcgcctgg tgcagctgct ccgccagcac agcagcccct 
       gtgtctgggg gcagcggacc acgtcgacga ggcggtcgtg tcgtcgggga 
       >.......................hTERT........................> 
       d  t  d  p   r  r  l   v  q  l   l  r  q  h   s  s  p 
 
 1851  ggcaggtgta cggcttcgtg cgggcctgcc tgcgccggct ggtgccccca 
       ccgtccacat gccgaagcac gcccggacgg acgcggccga ccacgggggt 
       >.......................hTERT........................> 
        w  q  v   y  g  f  v   r  a  c   l  r  r   l  v  p  p 
 
 1901  ggcctctggg gctccaggca caacgaacgc cgcttcctca ggaacaccaa 
       ccggagaccc cgaggtccgt gttgcttgcg gcgaaggagt ccttgtggtt 
       >.......................hTERT........................> 
         g  l  w   g  s  r   h  n  e  r   r  f  l   r  n  t 
 
 1951  gaagttcatc tccctgggga agcatgccaa gctctcgctg caggagctga 
       cttcaagtag agggacccct tcgtacggtt cgagagcgac gtcctcgact 
       >.......................hTERT........................> 
       k  k  f  i   s  l  g   k  h  a   k  l  s  l   q  e  l 
 
 2001  cgtggaagat gagcgtgcgg ggctgcgctt ggctgcgcag gagcccaggg 
       gcaccttcta ctcgcacgcc ccgacgcgaa ccgacgcgtc ctcgggtccc 
       >.......................hTERT........................> 
        t  w  k   m  s  v  r   g  c  a   w  l  r   r  s  p  g 
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 2051  gttggctgtg ttccggccgc agagcaccgt ctgcgtgagg agatcctggc 
       caaccgacac aaggccggcg tctcgtggca gacgcactcc tctaggaccg 
       >.......................hTERT........................> 
         v  g  c   v  p  a   a  e  h  r   l  r  e   e  i  l 
 
 2101  caagttcctg cactggctga tgagtgtgta cgtcgtcgag ctgctcaggt 
       gttcaaggac gtgaccgact actcacacat gcagcagctc gacgagtcca 
       >.......................hTERT........................> 
       a  k  f  l   h  w  l   m  s  v   y  v  v  e   l  l  r 
 
 2151  ctttctttta tgtcacggag accacgtttc aaaagaacag gctctttttc 
       gaaagaaaat acagtgcctc tggtgcaaag ttttcttgtc cgagaaaaag 
       >.......................hTERT........................> 
        s  f  f   y  v  t  e   t  t  f   q  k  n   r  l  f  f 
 
 2201  taccggaaga gtgtctggag caagttgcaa agcattggaa tcagacagca 
       atggccttct cacagacctc gttcaacgtt tcgtaacctt agtctgtcgt 
       >.......................hTERT........................> 
         y  r  k   s  v  w   s  k  l  q   s  i  g   i  r  q 
 
 2251  cttgaagagg gtgcagctgc gggagctgtc ggaagcagag gtcaggcagc 
       gaacttctcc cacgtcgacg ccctcgacag ccttcgtctc cagtccgtcg 
       >.......................hTERT........................> 
       h  l  k  r   v  q  l   r  e  l   s  e  a  e   v  r  q 
 
 2301  atcgggaagc caggcccgcc ctgctgacgt ccagactccg cttcatcccc 
       tagcccttcg gtccgggcgg gacgactgca ggtctgaggc gaagtagggg 
       >.......................hTERT........................> 
        h  r  e   a  r  p  a   l  l  t   s  r  l   r  f  i  p 
 
 2351  aagcctgacg ggctgcggcc gattgtgaac atggactacg tcgtgggagc 
       ttcggactgc ccgacgccgg ctaacacttg tacctgatgc agcaccctcg 
       >.......................hTERT........................> 
         k  p  d   g  l  r   p  i  v  n   m  d  y   v  v  g 
 
 2401  cagaacgttc cgcagagaaa agagggccga gcgtctcacc tcgagggtga 
       gtcttgcaag gcgtctcttt tctcccggct cgcagagtgg agctcccact 
       >.......................hTERT........................> 
       a  r  t  f   r  r  e   k  r  a   e  r  l  t   s  r  v 
 
 2451  aggcactgtt cagcgtgctc aactacgagc gggcgcggcg ccccggcctc 
       tccgtgacaa gtcgcacgag ttgatgctcg cccgcgccgc ggggccggag 
       >.......................hTERT........................> 
        k  a  l   f  s  v  l   n  y  e   r  a  r   r  p  g  l 
 
 2501  ctgggcgcct ctgtgctggg cctggacgat atccacaggg cctggcgcac 
       gacccgcgga gacacgaccc ggacctgcta taggtgtccc ggaccgcgtg 
       >.......................hTERT........................> 
         l  g  a   s  v  l   g  l  d  d   i  h  r   a  w  r 
 
 2551  cttcgtgctg cgtgtgcggg cccaggaccc gccgcctgag ctgtactttg 
       gaagcacgac gcacacgccc gggtcctggg cggcggactc gacatgaaac 
       >.......................hTERT........................> 
       t  f  v  l   r  v  r   a  q  d   p  p  p  e   l  y  f 
 
 2601  tcaaggtgga tgtgacgggc gcgtacgaca ccatccccca ggacaggctc 
       agttccacct acactgcccg cgcatgctgt ggtagggggt cctgtccgag 
       >.......................hTERT........................> 
        v  k  v   d  v  t  g   a  y  d   t  i  p   q  d  r  l 
 
 2651  acggaggtca tcgccagcat catcaaaccc cagaacacgt actgcgtgcg 
       tgcctccagt agcggtcgta gtagtttggg gtcttgtgca tgacgcacgc 
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       >.......................hTERT........................> 
         t  e  v   i  a  s   i  i  k  p   q  n  t   y  c  v 
 
 2701  tcggtatgcc gtggtccaga aggccgccca tgggcacgtc cgcaaggcct 
       agccatacgg caccaggtct tccggcgggt acccgtgcag gcgttccgga 
       >.......................hTERT........................> 
       r  r  y  a   v  v  q   k  a  a   h  g  h  v   r  k  a 
 
 2751  tcaagagcca cgtctctacc ttgacagacc tccagccgta catgcgacag 
       agttctcggt gcagagatgg aactgtctgg aggtcggcat gtacgctgtc 
       >.......................hTERT........................> 
        f  k  s   h  v  s  t   l  t  d   l  q  p   y  m  r  q 
 
 2801  ttcgtggctc acctgcagga gaccagcccg ctgagggatg ccgtcgtcat 
       aagcaccgag tggacgtcct ctggtcgggc gactccctac ggcagcagta 
       >.......................hTERT........................> 
         f  v  a   h  l  q   e  t  s  p   l  r  d   a  v  v 
 
 2851  cgagcagagc tcctccctga atgaggccag cagtggcctc ttcgacgtct 
       gctcgtctcg aggagggact tactccggtc gtcaccggag aagctgcaga 
       >.......................hTERT........................> 
       i  e  q  s   s  s  l   n  e  a   s  s  g  l   f  d  v 
 
 2901  tcctacgctt catgtgccac cacgccgtgc gcatcagggg caagtcctac 
       aggatgcgaa gtacacggtg gtgcggcacg cgtagtcccc gttcaggatg 
       >.......................hTERT........................> 
        f  l  r   f  m  c  h   h  a  v   r  i  r   g  k  s  y 
 
 2951  gtccagtgcc aggggatccc gcagggctcc atcctctcca cgctgctctg 
       caggtcacgg tcccctaggg cgtcccgagg taggagaggt gcgacgagac 
       >.......................hTERT........................> 
         v  q  c   q  g  i   p  q  g  s   i  l  s   t  l  l 
 
 3001  cagcctgtgc tacggcgaca tggagaacaa gctgtttgcg gggattcggc 
       gtcggacacg atgccgctgt acctcttgtt cgacaaacgc ccctaagccg 
       >.......................hTERT........................> 
       c  s  l  c   y  g  d   m  e  n   k  l  f  a   g  i  r 
 
 3051  gggacgggct gctcctgcgt ttggtggatg atttcttgtt ggtgacacct 
       ccctgcccga cgaggacgca aaccacctac taaagaacaa ccactgtgga 
       >.......................hTERT........................> 
        r  d  g   l  l  l  r   l  v  d   d  f  l   l  v  t  p 
 
 3101  cacctcaccc acgcgaaaac cttcctcagg accctggtcc gaggtgtccc 
       gtggagtggg tgcgcttttg gaaggagtcc tgggaccagg ctccacaggg 
       >.......................hTERT........................> 
         h  l  t   h  a  k   t  f  l  r   t  l  v   r  g  v 
 
 3151  tgagtatggc tgcgtggtga acttgcggaa gacagtggtg aacttccctg 
       actcataccg acgcaccact tgaacgcctt ctgtcaccac ttgaagggac 
       >.......................hTERT........................> 
       p  e  y  g   c  v  v   n  l  r   k  t  v  v   n  f  p 
 
 3201  tagaagacga ggccctgggt ggcacggctt ttgttcagat gccggcccac 
       atcttctgct ccgggaccca ccgtgccgaa aacaagtcta cggccgggtg 
       >.......................hTERT........................> 
        v  e  d   e  a  l  g   g  t  a   f  v  q   m  p  a  h 
 
 3251  ggcctattcc cctggtgcgg cctgctgctg gatacccgga ccctggaggt 
       ccggataagg ggaccacgcc ggacgacgac ctatgggcct gggacctcca 
       >.......................hTERT........................> 
         g  l  f   p  w  c   g  l  l  l   d  t  r   t  l  e 
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 3301  gcagagcgac tactccagct atgcccggac ctccatcaga gccagtctca 
       cgtctcgctg atgaggtcga tacgggcctg gaggtagtct cggtcagagt 
       >.......................hTERT........................> 
       v  q  s  d   y  s  s   y  a  r   t  s  i  r   a  s  l 
 
 3351  ccttcaaccg cggcttcaag gctgggagga acatgcgtcg caaactcttt 
       ggaagttggc gccgaagttc cgaccctcct tgtacgcagc gtttgagaaa 
       >.......................hTERT........................> 
        t  f  n   r  g  f  k   a  g  r   n  m  r   r  k  l  f 
 
 3401  ggggtcttgc ggctgaagtg tcacagcctg tttctggatt tgcaggtgaa 
       ccccagaacg ccgacttcac agtgtcggac aaagacctaa acgtccactt 
       >.......................hTERT........................> 
         g  v  l   r  l  k   c  h  s  l   f  l  d   l  q  v 
 
 3451  cagcctccag acggtgtgca ccaacatcta caagatcctc ctgctgcagg 
       gtcggaggtc tgccacacgt ggttgtagat gttctaggag gacgacgtcc 
       >.......................hTERT........................> 
       n  s  l  q   t  v  c   t  n  i   y  k  i  l   l  l  q 
 
 3501  cgtacaggtt tcacgcatgt gtgctgcagc tcccatttca tcagcaagtt 
       gcatgtccaa agtgcgtaca cacgacgtcg agggtaaagt agtcgttcaa 
       >.......................hTERT........................> 
        a  y  r   f  h  a  c   v  l  q   l  p  f   h  q  q  v 
 
 3551  tggaagaacc ccacattttt cctgcgcgtc atctctgaca cggcctccct 
       accttcttgg ggtgtaaaaa ggacgcgcag tagagactgt gccggaggga 
       >.......................hTERT........................> 
         w  k  n   p  t  f   f  l  r  v   i  s  d   t  a  s 
 
 3601  ctgctactcc atcctgaaag ccaagaacgc agggatgtcg ctgggggcca 
       gacgatgagg taggactttc ggttcttgcg tccctacagc gacccccggt 
       >.......................hTERT........................> 
       l  c  y  s   i  l  k   a  k  n   a  g  m  s   l  g  a 
 
 3651  agggcgccgc cggccctctg ccctccgagg ccgtgcagtg gctgtgccac 
       tcccgcggcg gccgggagac gggaggctcc ggcacgtcac cgacacggtg 
       >.......................hTERT........................> 
        k  g  a   a  g  p  l   p  s  e   a  v  q   w  l  c  h 
 
 3701  caagcattcc tgctcaagct gactcgacac cgtgtcacct acgtgccact 
       gttcgtaagg acgagttcga ctgagctgtg gcacagtgga tgcacggtga 
       >.......................hTERT........................> 
         q  a  f   l  l  k   l  t  r  h   r  v  t   y  v  p 
 
 3751  cctggggtca ctcaggacag cccagacgca gctgagtcgg aagctcccgg 
       ggaccccagt gagtcctgtc gggtctgcgt cgactcagcc ttcgagggcc 
       >.......................hTERT........................> 
       l  l  g  s   l  r  t   a  q  t   q  l  s  r   k  l  p 
 
 3801  ggacgacgct gactgccctg gaggccgcag ccaacccggc actgccctca 
       cctgctgcga ctgacgggac ctccggcgtc ggttgggccg tgacgggagt 
       >.......................hTERT........................> 
        g  t  t   l  t  a  l   e  a  a   a  n  p   a  l  p  s 
 
 3851  gacttcaaga ccatcctgga ctgagtcgac cctgtggaat gtgtgtcagt 
       ctgaagttct ggtaggacct gactcagctg ggacacctta cacacagtca 
       >.........hTERT.........>> 
         d  f  k   t  i  l   d  - 
 
 3901  tagggtgtgg aaagtcccca ggctccccag caggcagaag tatgcaaagc 
       atcccacacc tttcaggggt ccgaggggtc gtccgtcttc atacgtttcg 
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 3951  atgcatctca attagtcagc aaccaggtgt ggaaagtccc caggctcccc 
       tacgtagagt taatcagtcg ttggtccaca cctttcaggg gtccgagggg 
 
 4001  agcaggcaga agtatgcaaa gcatgcatct caattagtca gcaaccatag 
       tcgtccgtct tcatacgttt cgtacgtaga gttaatcagt cgttggtatc 
 
 4051  tcccgcccct aactccgccc atcccgcccc taactccgcc cagttccgcc 
       agggcgggga ttgaggcggg tagggcgggg attgaggcgg gtcaaggcgg 
 
 4101  cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 
       gtaagaggcg gggtaccgac tgattaaaaa aaataaatac gtctccggct 
 
 4151  ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg 
       ccggcggagc cggagactcg ataaggtctt catcactcct ccgaaaaaac 
 
 4201  gaggcctagg cttttgcaaa aagcttacca tgaccgagta caagcccacg 
       ctccggatcc gaaaacgttt ttcgaatggt actggctcat gttcgggtgc 
 
 4251  gtgcgcctcg ccacccgcga cgac 
       cacgcggagc ggtgggcgct gctg 
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List of abbreviation 
ALP Alkaline phosphatase 
ARF Alternative reading frame, p14 
ATM Ataxia telangiectasia mutated 
CD Cluster of differentiation 
CDK Cyclin-dependent kinase 
CDKN1A Cyclin-dependent kinase inhibitor 1A, p21 
CDS Coding domain sequence 
Cfba1/Runx2   Core-binding factor 1/Runt-related transcription factor 2 
c-myc v-myc myelocytomatosis viral oncogene homolog 
Col I    Collagen type I 
DBCCR1 Deleted in bladder cancer chromosome region candidate 1 
DMEM Dulbecco's Modified Eagle's Medium 
DPX Di-n-butylPhthalate in Xylene 
E2F E2F transcription factors 
EDTA Ethylene diamine tetraacetic acid 
FBS Fetal bovine serum 
FISH Fluorescence in situ hybridization 
GO Gene ontology 
GOI Gene of interest 
HA Hyaluronic acid 
H-CAM Homing-associated cell adhesion molecule 
HIV human immunodeficiency virus 
hMSCs human mesenchymal stem cells 
hTERT human telomerase reverse transcriptase 
IBMX 3-Isobutyl-1-methylxanthin 
INK4a(Cdkn2a) Cyclin-dependent kinase inhibitor 2A, p16 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
LCA Leukocyte common antigen 
LPS Lipopolysaccharide 
LTR Long terminal repeats 
MCS Multiple cloning site 
MDM2 Mouse double minute 2 homolog 
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MMPs Matrix metalloproteinases 
MoMLV Moloney Leukemia Virus 
NRAS Neuroblastoma RAS viral oncogene homolog 
OC Osteocalcin 
PBS Phosphate-buffered saline 
PDL Cumulative population doubling level 
PDT Population doubling time 
Retinoblastoma 1 RB1 
ROS Reactive oxygen species 
RTCGD Retrovirus tagged cancer gene database 
RT-PCR Reverse transcription-polymerase chain reaction 
SC-1 Stem cell antigen-1 
SCP Single Cell Picking 
TERC Telomerase RNA component 
TGF-β Transforming growth factor beta 
TRAP Telomeric repeat amplification protocol 
TSS Transcription start site 
Tumor protein 53 TP53 
β –ME β-Mercaptoethanol 
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